慢性HCV和/或HBV感染者Th1、Th2主要细胞因子基因多态性研究
|
摘要
不同个体感染HCV和/或HBV后,临床表现复杂多样。约15%的感染者可自发清除病毒而免受疾病侵袭,约85%的感染者会转为慢性,并且在慢转者中约20%可进展为肝硬化,甚至原发性肝细胞癌。分析原因可能是病毒因素和宿主遗传因素综合作用的结果,但有报道认为即使是相同的病毒分离株在感染不同个体时其临床表现也有很大差异,因此宿主的遗传因素在丙型、乙型肝炎慢性化作用中起着重要作用。
据报道,不同个体对HCV和/或HBV感染所发生的免疫反应不同,个体间某些细胞因子的基因多态性可能导致机体免疫功能状态的差异,因而决定着HCV/HBV感染的不同临床转归。辅助性T细胞(Th)是免疫调节的核心细胞,在IFN-γ的作用下,Th0细胞可分化为Th1细胞,Th1主要分泌IL-2、IFN-γ等,通过介导细胞免疫,用于宿主的抗病毒、细胞毒效应、NK细胞自然杀伤作用等;在IL-4作用下,Th0细胞分化为Th2细胞,Th2主要分泌IL-4、IL-10等,刺激B淋巴细胞分化增殖产生抗体。Th1和Th2细胞因子的功能互相拮抗,Th1和Th2细胞功能的失衡将严重扰乱体液免疫和细胞免疫,进而影响着HCV、HBV感染者的慢性化和不同的临床转归。
目前,关于慢性HCV和/或HBV感染者体内Th1主要细胞因子IFN-γ、IL-2和Th2主要细胞因子IL-4、IL-10的表达水平报道尚不统一,与表达细胞因子水平相关的基因多态性研究尚处于起步阶段,并且结果报道各异。为此,本研究以不同感染类型:慢性HCV重叠HBV感染、单纯HCV感染、单纯HBV感染和健康对照及不同临床转归:轻型、中重型肝炎、肝硬化和健康对照为研究对象,探讨IFN-γ+T874A、IL-2-T330G、IL-4-C589T、IL-10-G1082A、IL-10-A592C的基因多态性与不同感染类型、临床转归、病毒复制和肝功异常的关系及各细胞因子基因多态性对临床转归有无交互作用,探讨HCV和/或HBV感染者不同临床转归的免疫遗传机制。
第一部分ELISA联合RT-n PCR检测慢性HCV感染者的结果分析
目的:对比酶联免疫吸附试验(ELISA)和逆转录-套式-聚合酶链反应(RT-n PCR)检测慢性丙型肝炎病毒感染者的抗-HCV和HCV RNA结果,为临床检测和血站筛选健康献血员提供参考依据。
方法:2005年5月对河北赵县某农村单采血浆还输血细胞HCV感染者133人及健康对照52人共185人采集空腹静脉血。该感染人群于1990年前单采血浆还输血细胞时感染、1993年经现场调查、血清生化指标及病原学标志检查确诊为HCV感染者、2002年追踪调查仍明确诊断者。用ELISA法检测抗-HCV,用RT-n PCR检测HCV RNA。
结果:①185份血清标本中,抗-HCV和HCV RNA均阳性者92份,占49.73%;抗-HCV阴性、HCV-RNA阳性18份,占9.73%;抗-HCV阳性、HCV-RNA阴性22份,占11.89%,两者均阴性53份,占28.65%。两种方法检测结果一致符合率为78.38%((92+53)/185),Kappa=0.548(u=8.65, P<0.01),另外用配对卡方检验两种方法不一致率亦无差别(χ2paried=0.40,P>0.05),均说明两种检测方法高度一致;②ELISA法检测慢性HCV感染者的灵敏度为82.71%,特异度为92.31%,漏诊率为17.29%;RT-n PCR检测的灵敏度为81.20%,特异度为96.15%,漏诊率为18.80%,两种方法检测灵敏度无差别(χ2=0.10,P>0.05);③并联试验检测灵敏度为96.75%,特异度为88.76%,其灵敏度明显高于单一ELISA法时的82.71%(χ2=9.62,P<0.01),也明显高于串联试验67.16%的灵敏度(χ2=29.39,P=0.00)。结论:单独用ELISA法检测抗-HCV约有17%的漏检率,同时用RT-n PCR检测HCV RNA,可明显提高HCV感染者的阳性检出率。
第二部分慢性HCV和/或HBV感染者Th1主要细胞因子基因多态性研究目的:研究Th1主要细胞因子基因IFN-γ+874和IL-2-330单核苷酸多态性(SNP)与单纯HCV、HBV感染及HCV重叠HBV感染、临床转归等的关系,探讨HCV/HBV感染者慢性化和临床转归的免疫遗传机制。
方法:用序列特异性引物-聚合酶链反应(PCR-SSP)和限制性内切酶片段长度多态性-聚合酶链反应(RFLP-PCR)技术检测了79例慢性HCV重叠HBV感染、55例单纯HCV感染、69例单纯HBV感染和74例健康对照者的IFN-γ+874 SNP和IL-2-330SNP,Beckman LX-20生化分析仪检测肝功,RT-n PCR检测HCV RNA。分析了IFN-γ+874和IL-2-330基因型和等位基因频率与慢性HBV/HCV感染、临床转归、ALT异常和HCV RNA表达等的关系。
结果:①不同感染类型与IFN-γ+874基因型频率有统计学关联(χ2=16.15, P=0.01),单纯HCV、HBV感染和HCV重叠HBV感染者AA基因型频率明显高于对照组,TA基因型频率明显低于对照组,携带AA基因型个体感染HCV、HBV和HCV重叠HBV感染的相对危险度(OR)及95%可信限(95%CI)分别是TA基因型的3.22(1.43~7.25)、2.70(1.24~5.92)、4.02倍(1.88~8.55);T、A等位基因频率与感染类型尚未发现统计学关联(χ2=4.87, P=0.18); HCV和/或HBV感染类型间基因型、等位基因频率差异均不明显(P>0.05)。不同感染类型IL-2-330基因型存在显著差异(χ2=14.24, P=0.03),单纯HCV、HBV感染和HCV重叠HBV感染者TT基因型频率明显高于对照组,GG基因型频率明显低于对照组,携带TT基因型个体感染HCV、HBV和HBV重叠HCV感染的OR及95%CI分别是GG基因型的3.46(1.17~10.02)、7.14(2.13~23.81)、2.93倍(1.15~7.46);T、G等位基因频率在感染类型间差异有统计学意义(χ2=12.33, P=0.01),携带T基因个体感染HCV、HBV、HCV重叠HBV的OR值和95%CI分别是G基因的1.82(1.09~3.03)、1.73(1.10~2.73)、2.26倍(1.39~3.69);HCV和/或HBV各感染类型间基因型和等位基因频率差异均不显著(P>0.05)。②不同临床转归类型IFN-γ+874基因型频率之间差异有统计学意义(χ2=14.78,P=0.02),轻型、中重型肝炎和肝硬化组AA基因型频率明显高于对照组,而TA基因型频率明显低于对照组;携带AA基因型个体进展为轻型、中重型肝炎、肝硬化的OR及95%CI分别是TA基因型的3.09(1.51~6.33 )、3.85(1.70~8.70)、3.14倍(1.08~9.17);T、A等位基因频率疾病转归尚未发现统计学关联(χ2=5.68, P=0.13)。不同疾病转归类型IL-2-330基因型频率差异存在显著的统计学意义(χ2=13.46,P=0.04),轻型、中重型肝炎和肝硬化组TT基因型频率明显高于对照组,GG基因型频率明显低于对照组;携带TT基因型个体进展为轻型、中重型肝炎、肝硬化的OR值及95%CI分别是GG基因型的3.42(1.45~8.13 )、3.29(1.10~9.80)、11.11倍(1.32~90.91);GG基因型频率与临床进展呈明显负相关(γ=-0.92,P<0.05);T、G等位基因频率与疾病转归有统计关联(χ2=11.69, P=0.01),携带T基因个体进展为轻型肝炎、中重肝炎和肝硬化的OR及95%CI分别是G基因的1.83(1.20~2.80)、1.70(1.02~2.82)、2.75倍(1.32~5.63)。③IFN-γ+874基因型和等位基因频率与HCV病毒复制未发现统计学关联(χ2=2.36,P=0.31;χ2=1.92,P=0.17)。IL-2-330基因型和等位基因频率与HCV病毒复制亦无统计学关联(χ2=0.83,P=0.66;χ2=1.97,P=0.66);④IFN-γ+874基因型和等位基因频率与ALT异常未发现统计学关联(χ2=0.23,P=0.89;χ2=0.12,P=0.74)。IL-2-330基因型频率和等位基因频率与ALT水平亦无统计学关联(χ2=1.35,P=0.51;χ2=0.24,P=0.62)。
结论:Th1主要细胞因子IFN-γ+874和IL-2-330基因多态性与HCV/HBV感染者慢性化及临床转归有明显的统计学关联,与病毒复制和肝功损伤无明显关联。IFN-γ+874AA基因型、IL-2-330 TT基因型和T等位基因可能是HCV和/或HBV感染及其临床转归的危险基因(型),IFN-γ+874 TA、IL-2-330 GG基因型和T等位基因可能为其保护基因(型)。
第三部分慢性HCV和/或HBV感染者Th2主要细胞因子基因多态性研究
目的:研究Th2主要细胞因子IL-4-589、IL-10-1082和IL-10-592基因多态性与单纯HCV、HBV感染及HCV重叠HBVV感染、临床转归等的关系,探讨HBV和/或HCV慢性感染者和不同临床转归的遗传易感机制。
方法:用SSP-PCR和RFLP-PCR技术检测79例HCV重叠HBV感染、55例单纯HCV感染、69例单纯HBV感染和74例健康对照者的IL-4-589 SNP、IL-10-1082和IL-10-592;用RT-n PCR方法检测血清HCV RNA;用Beckman LX-20全自动生化分析仪检测肝功能。
结果:①IL-4-589位点基因型和等位基因频率与不同感染类型无明显统计关联(χ2=4.41,P=0.62;χ2=0.26,P=0.97)。不同感染类型与IL-10-1082位点基因型频率有统计学关联(χ2=13.05, P=0.04),HBV和/或HCV感染者AA基因型频率明显高于对照组,而AG基因型频率明显低于对照组;携带AA基因型个体感染HCV、HBV、HCV重叠HBV的危险是AG基因型的2.34(1.07~5.10)、2.29 (1.10~4.78)、2.56倍(1.25~5.21);HCV和/或HBV各感染类型间基因型差异均不显著(P>0.05)。IL-10-1082等位基因频率与不同感染类型间无明显的统计关联(χ2=4.65,P=0.20)。IL-10-592位点基因型和等位基因频率与不同感染类型无明显统计关联(χ2=2.83,P=0.83;χ2=1.10,P=0.78)。②IL-4-589位点基因型和等位基因频率与临床转归类型无明显统计关联(χ2=4.58,P=0.60;χ2=2.46,P=0.48)。IL-10-1082位点基因型频率与不同临床转归类型有统计学关联(χ2=11.40, P=0.07),轻型、中重型肝炎和肝硬化组AA基因型频率明显高于健康对照组,而AG基因型频率明显低于健康对照;携带AA基因型个体进展为轻型、中重型肝炎和肝硬化的风险是AG基因型的2.03(1.03~3.98)、2.70(1.24~5.88)和4.26倍(1.59~ 11.36) ; IL-10-1082 AA基因型频率与临床转归呈明显正相关(γ=0.99,P<0.01),AG基因型频率与临床转归呈明显负相关(γ=-0.99,P<0.01);IL-10-1082等位基因频率与临床转归未见统计学关联(χ2=5.85, P=0.12);IL-10-592位点基因型和等位基因频率与临床转归无明显统计关联(χ2=2.50,P=0.87;χ2=0.92,P=0.82)。③IL-4-589位点基因型频率和等位基因与体内HCV病毒复制无统计学关联(χ2=1.53,P=0.47;χ2=1.24 P=0.27)。IL-10-1082位点基因型和等位基因频率与HCV病毒复制有统计学关联(χ2=12.27,P=0.00;χ2=5.36, P=0.02);病毒复制组AA基因型和A等位基因频率明显高于无病毒复制组,而AG基因型和G基因频率明显低于无病毒复制组(OR=3.36(1.67~6.76)、1.67倍(1.08~2.57));IL-10-592位点基因型频率和等位基因与体内有无HCV病毒复制无统计学关联(χ2=2.10,P=0.35;χ2=1.88,P=0.17)。④IL-4-589位点基因型和等位基因频率在ALT<80 U/L和≥80U/L间差异有明显的统计学意义(χ2=12.46,P=0.00;χ2=9.97, P=0.00),ALT≥80U/L组CT和CC基因型频率明显高于肝功<80U/L组,ALT≥80U/L组TT基因型频率明显低于肝功<80U/L组,携带CT和CC基因型个体肝功损伤的OR值和95%CI是TT基因型的3.43(1.47~8.00)、8.25倍(1.73~39.22);ALT≥80U/L组C等位基因频率明显高于肝功<80U/L组,T等基因频率明显低于肝功<80U/L组,携带C等位基因的个体其肝功异常的风险是T等位基因的2.31倍(1.36~3.93)。IL-10-1082位点基因型和等位基因频率与ALT水平无明显统计学关联(χ2=3.25,P=0.20;χ2=1.79, P=0.18)。IL-10-592位点基因型频率在ALT<80 U/L和≥80U/L间差异有显著性(χ2=6.32,P=0.04),ALT≥80U/L组AC基因型频率明显高于肝功<80U/L组,AC基因型个体ALT异常风险是AA基因型的2.83倍(1.26~6.37),而等位基因频率与肝功异常无明显统计关联(χ2=2.30,P=0.13)。
结论:Th2主要细胞因子IL-10-1082基因型与HCV和/或HBV感染类型、不同临床转归、病毒复制有明显的统计学关联,AA基因型可能是其危险基因型,AG基因型可能是其保护基因型;IL-10-592和IL-4-589位点多态性与HBV和/或HCV感染者的肝功损伤有一定联系,IL-10-592AC基因型、IL-4-589 CT、CC基因型和C等位基因可能是其危险基因(型),IL-10-592AA基因型、IL-4-589 TT基因型和T等位基因可能是其保护基因(型)。
第四部分Th1、Th2细胞因子基因多态性在慢性HCV和/或HBV感染者临床转归中的交互作用研究
目的:探讨Th1、Th2细胞因子基因多态性在慢性HCV和/或HBV感染者临床转归中的交互作用。
方法:用多因子降维法(MDR)分析Th1、Th2细胞因子基因多态性在慢性HCV和/或HBV感染者及临床转归中有无交互作用,患病风险用OR及95% CI评价,交互作用大小用交互作用指数(S)、交互作用归因比(API)、交互作用超额相对危险度(RERI)及95%可信限(95%CI)评价。
结果:①MDR分析Th1主要细胞因子基因多态性,发现IFN-γ+874、IL-2-330位点对慢性HCV/HBV感染者临床转归有明显的交互作用(P=0.00)。IFN-γ+874 AA和IL-2-330 TT基因型共存时,HCV/HBV感染者进展为轻型.中重型肝炎和肝硬化的OR值分别为10.1(2.8~ 36.0)、10.6(2.9~38.8)和13.6(4.9~66.8),分别是IFN-γ+874 AA基因型单独暴露的6.8、4.1和8.1倍,是IL-2-330 TT基因型单独暴露时的8.4、8.1和6.6倍;S分别为13.04.5.01和7.22;RERI分别为8.43(2.61~27.23)、7.65(2.50~23.42)和10.83(2.53~46.32);API分别为83.22%.72.44%和79.81%。②MDR分析Th2主要细胞因子基因多态性,发现IL-10-592和IL-4-589位点对慢性HCV和HBV感染者的肝脏炎症性损伤有明显的交互作用(P=0.00)。单独IL-10-592 AC基因型对慢性HCV/HBV感染者肝脏炎症性损伤无明显作用(OR=1.0),但IL-4-589 CC或CT和IL-10-592 AC共存时OR为5.5(2.6~11.5);S=7.10,RERI=3.70(2.11~6.49);API=67.64%。③MDR分析Th1、Th2主要细胞因子基因多态性交互作用,发现IFN-γ+874、IL-2-330和IL-10-1082三个位点对慢性HCV和HBV感染者的临床转归有明显交互作用(P=0.01)。若只考虑三种基因型的单独效应,对HCV/HBV感染者临床转归的危险性从大到小依次是IL-10-1082 AA基因型(OR=2.7,4.3,7.1)、IFN-γ+874 AA基因型(OR=2.0,3.9,2.4)和IL-2-330 TT基因型(OR=1.2,1.3,2.8),并且IL-10-1082 AA基因型与临床进展严重程度正相关(γ=0.99,P<0.05)。若考虑其中两种基因型的联合作用效应,IFN-γ+874 AA和IL-2-330 TT基因型共存时,感染者不同临床转归类型对应的OR值分别为7.5(2.0~28.4)、9.6(2.6~35.6)和10.7(1.4~ 80.2)(与单独分析IFN-γ+874 AA和IL-2-330 TT基因型的OR值不等,是因为存在IL-10-1082 AA基因型的交互作用),分别是IFN-γ+874 AA单基因型暴露的3.8、2.5和4.5倍,是IL-2-330 TT单基因型暴露的6.3、7.4和3.8倍;S分别为5.3、2.7和3.0,RERI分别为5.3(1.1~24.5)、5.41(1.8~16.2)和6.5(1.3~31.5),API分别为70.3%、56.4%、60.5%。IFN-γ+874 AA和IL-10-1082 AA共存时,感染者不同临床转归类型对应的OR值分别为1.6(1.0~2.5)、4.0(1.6~ 9.9)、5.3(1.5~ 19.1),均小于IL-10-1082 AA基因型单独作用的OR值(2.7、4.3、7.1);S分别为0.2、0.5、0.6,RERI分别为-2.1(-1.1~-4.1)、-3.2(-1.5~-6.8)、-3.2 (-1.3~ -7.6),API分别为-130.0%、-79.5%、-59.1%。IL-2-330 TT和IL-10-1082 AA基因型共存时,感染者不同临床转归类型对应的OR值分别为3.0(1.3~7.2)、4.5(1.6~12.3)和8.5(2.0~35.7),与IL-10-1082 AA基因型单独暴露时的OR值(2.7、4.3、7.1)相差不大;S分别为1.1、1.0、1.0,RERI分别为0.1、-0.1、-0.4,API分别为3.7%、0.0%、-0.4%。当IFN-γ+874 AA、IL-2-330 TT和IL-10-1082 AA三种基因型共存时,感染者不同临床转归类型对应的OR值分别为9.6(2.9~31.8)、12.8 ( 2.0~80.2 )和32.0(5.1~200.9),是IFN-γ+874 AA、IL-2-330 TT共存时OR值的1.3、1.3和3.0倍;S分别为1.1、1.0、2.0,API为4.2%、-0.8%和47.5%,RERI为0.4(0.2~0.7)、-0.1(0.0~0.5)和15.2(3.6~64.3)。
结论:Th1主要细胞因子IFN-γ+874 AA、IL-2-330 TT基因型对慢性HCV/HBV感染者不良临床转归有明显的协同作用;Th2主要细胞因子IL-4-589 CC或CT和IL-10-592 AC基因型对慢性HCV/HBV感染者肝脏炎症性损伤有明显的协同作用;Th1主要细胞因子基因型IFN-γ+874 AA、IL-2-330 TT和Th2主要细胞因子基因型IL-10-1082 AA对慢性HCV/HBV感染者进展为轻型、中重型肝炎交互作用不明显,对进展为肝硬化有协同作用。
Infection with the hepatitis C virus (HCV) and/or hepatitis B virus (HBV) is characterized by a broad spectrum of possible outcomes. Infection is self-limited in a very minority, while the majority of infections develop persistent infection. Among those individuals with persistent HCV and/or HBV infection, the majority develops chronic hepatitis, some progress to fibrosis and even primary hepatocellular carcinoma. The variation may be attributable to viral and host genetic background. However it has been reported that the natural outcome in HCV or HBV infection varies among individuals though infected by the same viral. So there is strong evidence in HCV/HBV infection that host genetic factors play a major role in determining the outcome of infection.
The immunity responses to HCV and HBV infection vary among individuals to a far extent. The single nucleotide polymorphism (SNP) in some cytokines gene greatly influences the clinical outcome of individuals with HCV and HBV infection. Helper T cell (Th) plays a key role in mediated immunity. Th1 cell is produced by the origin of Th in the stimulation of interferon-gamma and Th1 secrete cytokines such as interleukin 2, interferon-gamma, and so on. Th1 cytokines participate in cell-mediated immunity for controlling such intracellular pathogens as viruses, cytotoxic T lymphocyte (CTL) proliferation and activation, and natural killer cells (NK) activation. Th2 cell is produced by the origin of Th with the stimulation of interleukin 4. The major lymphokines secreted by Th2 cell are interleukin 4, interleukin 10 and so on. Th2 cytokines are essential for antibody-mediated immunity by proliferating and activating the B lymphocell. The cytokines from Th1 cells inhibit Th2 cells, and vice versa. The imbalance of Th1 and Th2 heavily disturbed the balance between the cell-mediated immunity and antibody-mediated immunity, which may be the key to the clinical outcome of chronic HCV and/or HBV infection.
There is compelling evidence that cytokines play a significant role in chronic HCV and HBV disease pathogenesis. However, contradictory reports exist as to the exact effect of the cytokines promoter polymorphisms on the natural outcome of HCV and HBV infection. In order to explore the possible association of the cytokines gene polymorphism with the susceptibility of chronic HCV/HBV infection and the outcome of these infections, the IFN-γ+874, IL-2-330, IL-4-589, IL-10-1082, IL-10-592 gene polymorphisms were studied in subjects of mild hepatitis, moderate and severe hepatitis, and cirrhosis infected with HCV, HBV, HCV co-infected with HBV. These results would explore the immune genetic mechanisms of the clinical outcome of HCV and HBV infection.
Part 1 Result comparison of anti-HCV detected by ELISA and HCV RNA detected by RT-n PCR in chronic hepatitis C virus infection
Objective: In order to provide the basis for the clinical test and the blood station screening the health donator, the results of anti-HCV tested by enzyme-linked-immuno-absorbed assay (ELISA) and HCV RNA tested by Reverse-Transcript–nested-Polymerase-Chain-Reaction (RT-n PCR) were compared in the chronic HCV infection.
Methods: Venous blood samples of 133 chronic HCV infections, which were infected with HCV nearly in 1990 through plasma donator and diagnosed in 1993 in a rural area of Zhao County of Hebei Province, and 52 health controls were collected in May 2005. The antibody to HCV was tested by ELISA method and HCV RNA was tested by RT-n PCR method.
Results:①In 185 cases, the rate of both anti-HCV and HCV RNA positive was 49.73% (92/185). The rate of anti-HCV negative but HCV RNA positive was 9.73% (18/185). The rate of anti-HCV positive but HCV RNA negative was 11.89% (22/185). The rate of both anti-HCV and HCV RNA negative was 28.65% (53/185). The result-agreement rate of ELISA and RT-n PCR testing methods was 78.38% ((92+53)/185). Kappa value equals 0.548 (u=8.65, P<0.01). The disagreement rate was not obviously different between ELISA and RT-n PCR testing methods (χ2 paired =0.40, P>0.05), which illustrated high agreement between the ELISA and RT-nPCR methods.②In the diagnosis of chronic HCV infection, the sensitivity of anti-HCV tested by ELISA was 82.71%, the specificity was 92.31%, and the omitting rate was 17.29%. The sensitivity of HCV RNA tested by RT-n PCR was 81.20%, and the specificity was 96.15%, and the omitting rate was 18.80%. The sensitivity was not obviously different between ELISA and RT-n PCR (χ2=0.10,P>0.05).③The sensitivity tested by ELISA parallel with RT-n PCR was 96.75%, which was obviously higher than that of single ELISA (82.71%) (χ2=9.62,P=0.00) and ELISA series with RT-n PCR(χ2=29.39, P=0.00).
Conclusion: The false negative rate was nearly 17% when anti-HCV was used to detect HCV infection. The positive testing rate of HCV infection was increased remarkably when ELISA and RT-n PCR were used simultaneously. Part 2 The study of Th1 cytokine SNP in chronic HCV and/or HBV infection
Objective: To explore the possible association of the polymorphisms in interferon-gamma gene intron 1 at position +874 (IFN-γ+874), interleukin-2 gene at position–330 (IL-2-330) with the susceptibility of HCV and/or HBV infection and the outcome of these infections.
Methods: IFN-γ+874 gene and IL-2-330 gene SNP were detected in 277 subjects including 79 chronic HCV co-HBV infection, 55 individuals only with HCV infection, 69 individuals only with HBV infection and 74 healthy controls, by sequence specific primers-PCR (SSP-PCR) and by restricted fragment long polymorphism-PCR (RFLP-PCR). Hepatocellular injury as suggested by alanine aminotransferase (ALT) was detected by BeckmanLX-20. The presence or absence of viral particles in serum was determined by RT-nPCR. The possible association of the polymorphism of IFN-γ+874, IL-2-330 with the susceptibility of HCV and/or HBV infection and the outcome of these infections were analyzed.
Results:①IFN-γ+874 AA genotype frequency in individuals with chronic HCV, HBV, HCV co-HBV infection was significant higher than that in controls(χ2=16.15,P=0.01). Odds Ratio (OR) and 95% Confidence Interval (95% CI) of IFN-γ+874 AA genotype in chronic infection with HCV, HBV, HCV co- HBV were 3.22 (1.43~7.25), 2.70 (1.24~5.92) and 4.02 (1.88~8.55) compared with TA genotype. No significant differences were found among the HCV, HBV, HCV and HBV infections (P>0.05). There were no significant association of IFN-γ+874 A/T allele frequency with HCV/HBV infections (χ2=4.87, P=0.18); Chronic infection with HCV, HBV, HCV co-HBV was associated with higher IL-2-330 TT genotype frequency (χ2=14.24, P=0.03; OR (95%CI) = 3.46 (1.17~10.20), 7.14 (2.13~23.81), 2.93 (1.15~7.46)) and T allele frequency (χ2=12.33, P=0.01; OR (95%CI)=1.82 (1.09~3.03), 1.73 (1.10~ 2.73), 2.26 (1.39~3.69)). No significant differences were found among the HCV and / or HBV infections (P>0.05).②The outcome of mild chronic hepatitis (CH), moderate/severe CH and cirrhosis during HBV and/or HCV infection was associated with IFN-γ+874 AA genotype (χ2=14.78,P=0.02, OR=3.09 (1.51~6.33), 3.85 (1.70~8.70), 3.14 (1.08~9.17)); No significant relationships were found between IFN-γ+874 A/T allele frequency and the clinical outcome of HBV/HCV infection (χ2=5.68, P=0.13); The outcome of mild CH, moderate/severe CH and cirrhosis during HBV and/or HCV infection was associated with higher IL-2-330 TT genotype frequency (χ2=13.46, P=0.04; OR=3.42 (1.45~8.13), 3.29 (1.10~9.80), 11.11 (1.32~90.91)) and T allele frequency (χ2=11.69, p=0.01; OR=1.83 (1.20~2.80), 1.70 (1.02~2.82), 2.75 (1.32~5.63)), and the IL-2 (-330) GG genotype frequency showed negative correlation with the clinical progression (γ=-0.92, p<0.05).③There were no significant associations of IFN-γ+874 genotype / allele frequency with HCV duplication (χ2=2.36,P=0.31;χ2=1.92,P=0.17). No significant relationship was found between IL-2-330 genotype/allele frequency and HCV duplication (χ2=0.83,P=0.66;χ2=0.20,P=0.66).④There were no significant associations of IFN-γ+874 genotype/allele, IL-2-330 genotype/allele frequency with abnormal ALT (χ2=0.23,P=0.89;χ2=0.12, P=0.74;χ2=1.35,P=0.51;χ2=0.24, P=0.62).
Conclusion: These results suggest that polymorphisms in the IFN-γ+874, IL-2-330 appear to have some influence on the chronic HCV and/or HBV infection, and on the outcome of HCV and/or HBV infections. IFN-γ+874AA, IL-2-330 TT genotype and T allele are possible risk to the chronic HCV and/or HBV infection and to the outcome of HCV and/or HBV infection, however IFN-γ+874 TA, IL-2-330 GG genotype and G allele is possible protective to them.
Part 3 The study of Th2 cytokine SNP in chronic HCV and/or HBV infection
Objective: To explore the possible associations of the polymorphism of interleukin-4 (IL-4) gene at position–589, interleukin-10 (IL-10) gene at position -1082, -592 with the susceptibility of hepatitis C and/or hepatitis B virus infection and the outcome of these infections.
Methods: IL-4-589, IL-10-1082, IL-10-592 gene SNP were detected in 277 subjects including 79 HCV co-HBV infection, 55 individuals only with HCV infection, 69 individuals only with HBV infection and 74 health control, by SSP-PCR and RFLP-PCR. Hepato-cellular injury as suggested by ALT was detected by BeckmanLX-20. The presence or absence of viral particles in serum was determined by RT-nPCR. The possible associations of the polymorphisms of IL-4-589, IL-10-1082 and IL-10-592 with the susceptibility of HCV and/or HBV infection and the outcome of these infections were analyzed.
Results:①Chronic infection with HCV, HBV, HCV co-HBV was not associated with IL-4-589 genotype and allele (χ2=4.41,P=0.62;χ2=0.26,P=0.97); Chronic infection with HCV, HBV, HCV and HBV was associated with higher IL-10-1082 AA genotype frequency (χ2=13.05, P=0.04; OR=2.34 (1.07~5.10), 2.29 (1.10~4.78), 2.56 (1.25~5.21)). However no significant differences were found among the HCV, HBV, HCV and HBV infection (P>0.05). There were no significant association of IL-10-1082 allele frequency among HCV, HBV and HCV co-HBV infections (χ2=4.65,P=0.20).
There were no significant association of IL-10-592 genotype and allele frequency with chronic HBV and/or HCV infection(χ2=2.83,P=0.83;χ2=1.10,P=0.78);②The outcome of mild CH, moderate/severe CH and cirrhosis during HBV and/or HCV infection was associated with IL-10-1082 AA genotype frequency (χ2=11.40, p=0.07; OR=2.03 (1.03~3.98), 2.70 (1.24~5.88), 4.26 (1.59~11.36)), and the IL-10-1082 AA genotype frequency showed positive correlation with the clinical outcome (γ=-0.99, p<0.01), however IL-10-1082 AG genotype frequency showed negative correlation with the clinical outcome (γ=-0.99, p<0.01). There were no significant associations of IL-10-1082 allele frequency, IL-10-592 genotype and allele frequency with HCV/HBV infection and clinical outcome (χ2=5.85, P=0.12;χ2=2.50, P=0.87;χ2=0.92, P=0.82); The outcome of mild CH, moderate/severe CH and cirrhosis during HBV and/or HCV infection was not associated with IL-4-589 genotype and allele frequency (χ2=4.58, P=0.60;χ2=2.46, P=0.48).③There were obviously associations of IL-10-1082 higher AA genotype frequency and A allele frequency with HCV replication (χ2=12.27, P=0.00;χ2=5.36, P=0.02). The risk of subjects with AA genotype or A allele was 3.36 times (1.67~6.76), 1.67 times (1.08~2.57) than that with AG genotype and G allele; There were no significant associations of IL-10-592, IL-4-589 genotype/allele frequency with HCV replication (χ2=2.10, P=0.35;χ2=1.88, P=0.17;χ2=1.53, P=0.47;χ2=1.24, P=0.27).④There were no significant associations of IL-10-1082 genotype and allele frequency and IL-10-592 allele frequency with abnormal ALT (χ2=3.25, P=0.20;χ2=1.79, P=0.18;χ2=2.30, P=0.13); Abnormal ALT level was associated with higher IL-10-592 AC genotype (χ2=6.32, P=0.04; OR=2.83(1.26~6.37)); Abnormal serum ALT level was associated with IL-4-589 CC and CT genotype (χ2=12.46, P=0.00; OR=8.25 (1.74~ 39.22), 3.43 (1.47~8.00)) and the C allele (χ2=9.97, P=0.00, OR=2.31 (1.36~3.93)).
Conclusion: These results suggest that polymorphism in the IL-10-1082 appears to have some influence on the chronic HCV and/or HBV infection, and on the outcome of HCV and/or HBV infections and HCV replication. IL-10-1082 AA genotype is possible risk to the chronic HCV, HBV and HCV co-HBV infection and the clinical outcome, however AG genotype is possible protective to them. IL-10-592 AC genotype frequency has influence on the liver damage, and IL-4-589 CT, CC genotype, and C allele are possible risk to the liver inflammatory injury, and TT genotype and T allele is possible protective to it.
Part 4 The interaction of Th1 and Th2 cytokine SNP in the clinical outcome infected with chronic HCV and/or HBV
Objective: To analyze the interaction of the Th1 and Th2 cytokine SNP in HCV/HBV infection and in the outcome of these infections. Methods: The interaction of the Th1 and Th2 cytokine SNP in HCV and/ or HBV infection and the outcome of these infections was analyzed by multifactor dimensionality reduction (MDR). The OR was used to evaluate the risk of clinical outcome during HCV/HBV infection. The synergy index (S), Attributable proportion of interaction (API), Relative excess risk of interaction (RERI) and 95% CI were used to evaluate the interaction degree.
Results:①The interaction of IFN-γ+874 AA and IL-2-330 TT genotype was found in the clinical outcome of chronic HCV/HBV infection by MDR (P=0.00). When individuals carried with IFN-γ+874 AA genotype and IL-2-330 TT genotype, the OR and 95% CI for the HCV/HBV to develop to mild CH, moderate/severe CH and cirrhosis was 10.1(2.8~36.0), 10.6(2.9~38.8) and 13.6(4.9~66.8) respectively, and the OR in individuals with IFN-γ+874 AA and IL-2-330 TT was 6.8 times, 4.1 times and 6.6 times compared with individuals of only IFN-γ+874 AA, and was 8.4 times, 8.1 times and 6.6 times comparied with individuals of only. The S of chronic HCV/HBV infection developing to mild CH, moderate/severe CH and cirrhosis in IFN-γ+874 AA and IL-2-330 TT genotype was 13.04, 5.01 and 7.22 respectively. RERI and 95% CI were 8.43(2.61~27.23), 7.65(2.50~23.42) and 10.83(2.53~46.32). API was 83.22%, 72.44% and 79.81% respectively.②Interaction of IL-10-592 gene and IL-4-589 gene was found in the hepato-cellular injury of chronic HCV and / or HBV infection by MDR (P=0.00). When only with IL-10-592 AC, there was no significant effect on the hepato-cellular injury of chronic HCV/HBV infection (OR=1.0). However together with IL-4-589 CC or CT and IL-10-592 AC, the OR was 5.5 (2.6~11.5). It was found to have significant interaction to the hepato-cellular injury, which the S was 7.1, RERI was 3.7(2.11~6.49), and API was 67.6%.③The interaction of IFN-γ+874 gene, IL-2-330 gene and IL-10-1082 gene was found in the clinical outcome of chronic HCV/HBV infection by MDR (P=0.01). When one SNP were analyzed, the IL-10-1082 AA genotype had the highest risk (OR=2.7, 4.3, 7.1), IFN-γ+874 AA genotype had the middle risk (OR=2.0, 3.9, 2.4), IL-2-330 TT had the lowest risk (OR=1.2, 1.3, 2.8) to the outcome of HCV/HBV infection. The IL-10-1082 AA genotype was positive correlation with the clinical progression (γ=0.99, P<0.05). When two SNP were analyzed at a time, IFN-γ+874 AA genotype and IL-2-330 TT genotype had a high risk for the HCV/HBV to develop to mild CH, moderate/severe CH and cirrhosis, OR=7.5(2.0~28.4), 9.6(2.6~35.6) and 10.7(1.4~ 80.2)), which were not equal to the OR=10.1(2.8~36.0), 10.6(2.9~38.8) and 13.6(4.9~66.8) of IFN-γ+874 AA genotype and IL-2-330 TT genotype was due to with or without considering the interaction of IL-10-1082 AA genotype. The risk of both IFN-γ+874 AA genotype and IL-2-330 TT genotype in mild CH, moderate/severe CH and cirrhosis was 3.8 times, 2.5 times and 4.5 times comparied with only IFN-γ+874 AA genotype, and was 6.3 times, 7.4 times and 3.8 times comparied with only IL-2-330 TT genotype. The S was 5.3, 2.7 and 3.0 respectively , the RERI was 5.25(1.1~24.5), 5.41(1.8~16.2) and 6.5(1.3~31.5), the API was 70.28%, 56.35%, 60.54%. When together with IFN-γ+874 AA genotype and IL-10-1082 AA genotype, the OR in mild CH, moderate/severe CH and cirrhosis was 1.6(1.0~2.5), 4.0(1.6~9.9) and 5.3(1.5~ 19.1) respectively, which was lower than that with only IL-10-1082 AA genotype. The S was 0.22, 0.49, 0.58 respectively, the RERI was -2.1(-1.1~-4.1), -3.2(-1.5~ -6.8), -3.15 (-1.3~ -7.6) respectively, the API was -130.00%, -79.50%, -59.10% respectively. When together with IL-2-330 TT genotype and IL-10-1082 AA genotype, the OR in mild CH, moderate/severe CH and cirrhosis was 3.0(1.3~7.2), 4.5(1.6~12.3), 8.5(2.0~35.7), which was similar to the OR of only with IL-10-1082 AA genotype. S was 1.06, 0.98, 0.95 respectively, RERI was 0.11, -0.07, -0.42, API was 3.68%, -0.02%, -0.42%. When three SNPs were analyzed at a time, OR in mild CH, moderate/severe CH and cirrhosis was 9.6(2.9~31.8), 12.8(2.0~80.2) and 32.0(5.1~200.9). The OR was the 1.3 times, 1.3 times and 3.0 times compared with IFN-γ+874 AA and IL-2-330 TT. S was 1.1, 1.0 and 2.0, API was 4.2%, -0.8% and 47.5%, RERI was 0.4(0.2~0.7), -0.1(0.0~0.5) and 15.2(3.6~64.3) respectively.
Conclusion: These results suggest that subjects with IFN-γ+874 AA genotype and IL-2-330 TT genotype had higher risk for the clinical outcome of chronic HCV/HBV infection, the subjects with IL-10-592 AC genotype and IL-4-589 CC or CT genotype had a higher risk for the hepato-cellular injury of chronic HCV/HBV infection. IFN-γ+874 AA and IL-2-330 TT together with IL-10-1082 AA had no significant interaction for HCV/HBV infection to the mild CH, moderate and severe CH, however had positive interaction for HCV/HBV infection develop to cirrhosis.
据报道,不同个体对HCV和/或HBV感染所发生的免疫反应不同,个体间某些细胞因子的基因多态性可能导致机体免疫功能状态的差异,因而决定着HCV/HBV感染的不同临床转归。辅助性T细胞(Th)是免疫调节的核心细胞,在IFN-γ的作用下,Th0细胞可分化为Th1细胞,Th1主要分泌IL-2、IFN-γ等,通过介导细胞免疫,用于宿主的抗病毒、细胞毒效应、NK细胞自然杀伤作用等;在IL-4作用下,Th0细胞分化为Th2细胞,Th2主要分泌IL-4、IL-10等,刺激B淋巴细胞分化增殖产生抗体。Th1和Th2细胞因子的功能互相拮抗,Th1和Th2细胞功能的失衡将严重扰乱体液免疫和细胞免疫,进而影响着HCV、HBV感染者的慢性化和不同的临床转归。
目前,关于慢性HCV和/或HBV感染者体内Th1主要细胞因子IFN-γ、IL-2和Th2主要细胞因子IL-4、IL-10的表达水平报道尚不统一,与表达细胞因子水平相关的基因多态性研究尚处于起步阶段,并且结果报道各异。为此,本研究以不同感染类型:慢性HCV重叠HBV感染、单纯HCV感染、单纯HBV感染和健康对照及不同临床转归:轻型、中重型肝炎、肝硬化和健康对照为研究对象,探讨IFN-γ+T874A、IL-2-T330G、IL-4-C589T、IL-10-G1082A、IL-10-A592C的基因多态性与不同感染类型、临床转归、病毒复制和肝功异常的关系及各细胞因子基因多态性对临床转归有无交互作用,探讨HCV和/或HBV感染者不同临床转归的免疫遗传机制。
第一部分ELISA联合RT-n PCR检测慢性HCV感染者的结果分析
目的:对比酶联免疫吸附试验(ELISA)和逆转录-套式-聚合酶链反应(RT-n PCR)检测慢性丙型肝炎病毒感染者的抗-HCV和HCV RNA结果,为临床检测和血站筛选健康献血员提供参考依据。
方法:2005年5月对河北赵县某农村单采血浆还输血细胞HCV感染者133人及健康对照52人共185人采集空腹静脉血。该感染人群于1990年前单采血浆还输血细胞时感染、1993年经现场调查、血清生化指标及病原学标志检查确诊为HCV感染者、2002年追踪调查仍明确诊断者。用ELISA法检测抗-HCV,用RT-n PCR检测HCV RNA。
结果:①185份血清标本中,抗-HCV和HCV RNA均阳性者92份,占49.73%;抗-HCV阴性、HCV-RNA阳性18份,占9.73%;抗-HCV阳性、HCV-RNA阴性22份,占11.89%,两者均阴性53份,占28.65%。两种方法检测结果一致符合率为78.38%((92+53)/185),Kappa=0.548(u=8.65, P<0.01),另外用配对卡方检验两种方法不一致率亦无差别(χ2paried=0.40,P>0.05),均说明两种检测方法高度一致;②ELISA法检测慢性HCV感染者的灵敏度为82.71%,特异度为92.31%,漏诊率为17.29%;RT-n PCR检测的灵敏度为81.20%,特异度为96.15%,漏诊率为18.80%,两种方法检测灵敏度无差别(χ2=0.10,P>0.05);③并联试验检测灵敏度为96.75%,特异度为88.76%,其灵敏度明显高于单一ELISA法时的82.71%(χ2=9.62,P<0.01),也明显高于串联试验67.16%的灵敏度(χ2=29.39,P=0.00)。结论:单独用ELISA法检测抗-HCV约有17%的漏检率,同时用RT-n PCR检测HCV RNA,可明显提高HCV感染者的阳性检出率。
第二部分慢性HCV和/或HBV感染者Th1主要细胞因子基因多态性研究目的:研究Th1主要细胞因子基因IFN-γ+874和IL-2-330单核苷酸多态性(SNP)与单纯HCV、HBV感染及HCV重叠HBV感染、临床转归等的关系,探讨HCV/HBV感染者慢性化和临床转归的免疫遗传机制。
方法:用序列特异性引物-聚合酶链反应(PCR-SSP)和限制性内切酶片段长度多态性-聚合酶链反应(RFLP-PCR)技术检测了79例慢性HCV重叠HBV感染、55例单纯HCV感染、69例单纯HBV感染和74例健康对照者的IFN-γ+874 SNP和IL-2-330SNP,Beckman LX-20生化分析仪检测肝功,RT-n PCR检测HCV RNA。分析了IFN-γ+874和IL-2-330基因型和等位基因频率与慢性HBV/HCV感染、临床转归、ALT异常和HCV RNA表达等的关系。
结果:①不同感染类型与IFN-γ+874基因型频率有统计学关联(χ2=16.15, P=0.01),单纯HCV、HBV感染和HCV重叠HBV感染者AA基因型频率明显高于对照组,TA基因型频率明显低于对照组,携带AA基因型个体感染HCV、HBV和HCV重叠HBV感染的相对危险度(OR)及95%可信限(95%CI)分别是TA基因型的3.22(1.43~7.25)、2.70(1.24~5.92)、4.02倍(1.88~8.55);T、A等位基因频率与感染类型尚未发现统计学关联(χ2=4.87, P=0.18); HCV和/或HBV感染类型间基因型、等位基因频率差异均不明显(P>0.05)。不同感染类型IL-2-330基因型存在显著差异(χ2=14.24, P=0.03),单纯HCV、HBV感染和HCV重叠HBV感染者TT基因型频率明显高于对照组,GG基因型频率明显低于对照组,携带TT基因型个体感染HCV、HBV和HBV重叠HCV感染的OR及95%CI分别是GG基因型的3.46(1.17~10.02)、7.14(2.13~23.81)、2.93倍(1.15~7.46);T、G等位基因频率在感染类型间差异有统计学意义(χ2=12.33, P=0.01),携带T基因个体感染HCV、HBV、HCV重叠HBV的OR值和95%CI分别是G基因的1.82(1.09~3.03)、1.73(1.10~2.73)、2.26倍(1.39~3.69);HCV和/或HBV各感染类型间基因型和等位基因频率差异均不显著(P>0.05)。②不同临床转归类型IFN-γ+874基因型频率之间差异有统计学意义(χ2=14.78,P=0.02),轻型、中重型肝炎和肝硬化组AA基因型频率明显高于对照组,而TA基因型频率明显低于对照组;携带AA基因型个体进展为轻型、中重型肝炎、肝硬化的OR及95%CI分别是TA基因型的3.09(1.51~6.33 )、3.85(1.70~8.70)、3.14倍(1.08~9.17);T、A等位基因频率疾病转归尚未发现统计学关联(χ2=5.68, P=0.13)。不同疾病转归类型IL-2-330基因型频率差异存在显著的统计学意义(χ2=13.46,P=0.04),轻型、中重型肝炎和肝硬化组TT基因型频率明显高于对照组,GG基因型频率明显低于对照组;携带TT基因型个体进展为轻型、中重型肝炎、肝硬化的OR值及95%CI分别是GG基因型的3.42(1.45~8.13 )、3.29(1.10~9.80)、11.11倍(1.32~90.91);GG基因型频率与临床进展呈明显负相关(γ=-0.92,P<0.05);T、G等位基因频率与疾病转归有统计关联(χ2=11.69, P=0.01),携带T基因个体进展为轻型肝炎、中重肝炎和肝硬化的OR及95%CI分别是G基因的1.83(1.20~2.80)、1.70(1.02~2.82)、2.75倍(1.32~5.63)。③IFN-γ+874基因型和等位基因频率与HCV病毒复制未发现统计学关联(χ2=2.36,P=0.31;χ2=1.92,P=0.17)。IL-2-330基因型和等位基因频率与HCV病毒复制亦无统计学关联(χ2=0.83,P=0.66;χ2=1.97,P=0.66);④IFN-γ+874基因型和等位基因频率与ALT异常未发现统计学关联(χ2=0.23,P=0.89;χ2=0.12,P=0.74)。IL-2-330基因型频率和等位基因频率与ALT水平亦无统计学关联(χ2=1.35,P=0.51;χ2=0.24,P=0.62)。
结论:Th1主要细胞因子IFN-γ+874和IL-2-330基因多态性与HCV/HBV感染者慢性化及临床转归有明显的统计学关联,与病毒复制和肝功损伤无明显关联。IFN-γ+874AA基因型、IL-2-330 TT基因型和T等位基因可能是HCV和/或HBV感染及其临床转归的危险基因(型),IFN-γ+874 TA、IL-2-330 GG基因型和T等位基因可能为其保护基因(型)。
第三部分慢性HCV和/或HBV感染者Th2主要细胞因子基因多态性研究
目的:研究Th2主要细胞因子IL-4-589、IL-10-1082和IL-10-592基因多态性与单纯HCV、HBV感染及HCV重叠HBVV感染、临床转归等的关系,探讨HBV和/或HCV慢性感染者和不同临床转归的遗传易感机制。
方法:用SSP-PCR和RFLP-PCR技术检测79例HCV重叠HBV感染、55例单纯HCV感染、69例单纯HBV感染和74例健康对照者的IL-4-589 SNP、IL-10-1082和IL-10-592;用RT-n PCR方法检测血清HCV RNA;用Beckman LX-20全自动生化分析仪检测肝功能。
结果:①IL-4-589位点基因型和等位基因频率与不同感染类型无明显统计关联(χ2=4.41,P=0.62;χ2=0.26,P=0.97)。不同感染类型与IL-10-1082位点基因型频率有统计学关联(χ2=13.05, P=0.04),HBV和/或HCV感染者AA基因型频率明显高于对照组,而AG基因型频率明显低于对照组;携带AA基因型个体感染HCV、HBV、HCV重叠HBV的危险是AG基因型的2.34(1.07~5.10)、2.29 (1.10~4.78)、2.56倍(1.25~5.21);HCV和/或HBV各感染类型间基因型差异均不显著(P>0.05)。IL-10-1082等位基因频率与不同感染类型间无明显的统计关联(χ2=4.65,P=0.20)。IL-10-592位点基因型和等位基因频率与不同感染类型无明显统计关联(χ2=2.83,P=0.83;χ2=1.10,P=0.78)。②IL-4-589位点基因型和等位基因频率与临床转归类型无明显统计关联(χ2=4.58,P=0.60;χ2=2.46,P=0.48)。IL-10-1082位点基因型频率与不同临床转归类型有统计学关联(χ2=11.40, P=0.07),轻型、中重型肝炎和肝硬化组AA基因型频率明显高于健康对照组,而AG基因型频率明显低于健康对照;携带AA基因型个体进展为轻型、中重型肝炎和肝硬化的风险是AG基因型的2.03(1.03~3.98)、2.70(1.24~5.88)和4.26倍(1.59~ 11.36) ; IL-10-1082 AA基因型频率与临床转归呈明显正相关(γ=0.99,P<0.01),AG基因型频率与临床转归呈明显负相关(γ=-0.99,P<0.01);IL-10-1082等位基因频率与临床转归未见统计学关联(χ2=5.85, P=0.12);IL-10-592位点基因型和等位基因频率与临床转归无明显统计关联(χ2=2.50,P=0.87;χ2=0.92,P=0.82)。③IL-4-589位点基因型频率和等位基因与体内HCV病毒复制无统计学关联(χ2=1.53,P=0.47;χ2=1.24 P=0.27)。IL-10-1082位点基因型和等位基因频率与HCV病毒复制有统计学关联(χ2=12.27,P=0.00;χ2=5.36, P=0.02);病毒复制组AA基因型和A等位基因频率明显高于无病毒复制组,而AG基因型和G基因频率明显低于无病毒复制组(OR=3.36(1.67~6.76)、1.67倍(1.08~2.57));IL-10-592位点基因型频率和等位基因与体内有无HCV病毒复制无统计学关联(χ2=2.10,P=0.35;χ2=1.88,P=0.17)。④IL-4-589位点基因型和等位基因频率在ALT<80 U/L和≥80U/L间差异有明显的统计学意义(χ2=12.46,P=0.00;χ2=9.97, P=0.00),ALT≥80U/L组CT和CC基因型频率明显高于肝功<80U/L组,ALT≥80U/L组TT基因型频率明显低于肝功<80U/L组,携带CT和CC基因型个体肝功损伤的OR值和95%CI是TT基因型的3.43(1.47~8.00)、8.25倍(1.73~39.22);ALT≥80U/L组C等位基因频率明显高于肝功<80U/L组,T等基因频率明显低于肝功<80U/L组,携带C等位基因的个体其肝功异常的风险是T等位基因的2.31倍(1.36~3.93)。IL-10-1082位点基因型和等位基因频率与ALT水平无明显统计学关联(χ2=3.25,P=0.20;χ2=1.79, P=0.18)。IL-10-592位点基因型频率在ALT<80 U/L和≥80U/L间差异有显著性(χ2=6.32,P=0.04),ALT≥80U/L组AC基因型频率明显高于肝功<80U/L组,AC基因型个体ALT异常风险是AA基因型的2.83倍(1.26~6.37),而等位基因频率与肝功异常无明显统计关联(χ2=2.30,P=0.13)。
结论:Th2主要细胞因子IL-10-1082基因型与HCV和/或HBV感染类型、不同临床转归、病毒复制有明显的统计学关联,AA基因型可能是其危险基因型,AG基因型可能是其保护基因型;IL-10-592和IL-4-589位点多态性与HBV和/或HCV感染者的肝功损伤有一定联系,IL-10-592AC基因型、IL-4-589 CT、CC基因型和C等位基因可能是其危险基因(型),IL-10-592AA基因型、IL-4-589 TT基因型和T等位基因可能是其保护基因(型)。
第四部分Th1、Th2细胞因子基因多态性在慢性HCV和/或HBV感染者临床转归中的交互作用研究
目的:探讨Th1、Th2细胞因子基因多态性在慢性HCV和/或HBV感染者临床转归中的交互作用。
方法:用多因子降维法(MDR)分析Th1、Th2细胞因子基因多态性在慢性HCV和/或HBV感染者及临床转归中有无交互作用,患病风险用OR及95% CI评价,交互作用大小用交互作用指数(S)、交互作用归因比(API)、交互作用超额相对危险度(RERI)及95%可信限(95%CI)评价。
结果:①MDR分析Th1主要细胞因子基因多态性,发现IFN-γ+874、IL-2-330位点对慢性HCV/HBV感染者临床转归有明显的交互作用(P=0.00)。IFN-γ+874 AA和IL-2-330 TT基因型共存时,HCV/HBV感染者进展为轻型.中重型肝炎和肝硬化的OR值分别为10.1(2.8~ 36.0)、10.6(2.9~38.8)和13.6(4.9~66.8),分别是IFN-γ+874 AA基因型单独暴露的6.8、4.1和8.1倍,是IL-2-330 TT基因型单独暴露时的8.4、8.1和6.6倍;S分别为13.04.5.01和7.22;RERI分别为8.43(2.61~27.23)、7.65(2.50~23.42)和10.83(2.53~46.32);API分别为83.22%.72.44%和79.81%。②MDR分析Th2主要细胞因子基因多态性,发现IL-10-592和IL-4-589位点对慢性HCV和HBV感染者的肝脏炎症性损伤有明显的交互作用(P=0.00)。单独IL-10-592 AC基因型对慢性HCV/HBV感染者肝脏炎症性损伤无明显作用(OR=1.0),但IL-4-589 CC或CT和IL-10-592 AC共存时OR为5.5(2.6~11.5);S=7.10,RERI=3.70(2.11~6.49);API=67.64%。③MDR分析Th1、Th2主要细胞因子基因多态性交互作用,发现IFN-γ+874、IL-2-330和IL-10-1082三个位点对慢性HCV和HBV感染者的临床转归有明显交互作用(P=0.01)。若只考虑三种基因型的单独效应,对HCV/HBV感染者临床转归的危险性从大到小依次是IL-10-1082 AA基因型(OR=2.7,4.3,7.1)、IFN-γ+874 AA基因型(OR=2.0,3.9,2.4)和IL-2-330 TT基因型(OR=1.2,1.3,2.8),并且IL-10-1082 AA基因型与临床进展严重程度正相关(γ=0.99,P<0.05)。若考虑其中两种基因型的联合作用效应,IFN-γ+874 AA和IL-2-330 TT基因型共存时,感染者不同临床转归类型对应的OR值分别为7.5(2.0~28.4)、9.6(2.6~35.6)和10.7(1.4~ 80.2)(与单独分析IFN-γ+874 AA和IL-2-330 TT基因型的OR值不等,是因为存在IL-10-1082 AA基因型的交互作用),分别是IFN-γ+874 AA单基因型暴露的3.8、2.5和4.5倍,是IL-2-330 TT单基因型暴露的6.3、7.4和3.8倍;S分别为5.3、2.7和3.0,RERI分别为5.3(1.1~24.5)、5.41(1.8~16.2)和6.5(1.3~31.5),API分别为70.3%、56.4%、60.5%。IFN-γ+874 AA和IL-10-1082 AA共存时,感染者不同临床转归类型对应的OR值分别为1.6(1.0~2.5)、4.0(1.6~ 9.9)、5.3(1.5~ 19.1),均小于IL-10-1082 AA基因型单独作用的OR值(2.7、4.3、7.1);S分别为0.2、0.5、0.6,RERI分别为-2.1(-1.1~-4.1)、-3.2(-1.5~-6.8)、-3.2 (-1.3~ -7.6),API分别为-130.0%、-79.5%、-59.1%。IL-2-330 TT和IL-10-1082 AA基因型共存时,感染者不同临床转归类型对应的OR值分别为3.0(1.3~7.2)、4.5(1.6~12.3)和8.5(2.0~35.7),与IL-10-1082 AA基因型单独暴露时的OR值(2.7、4.3、7.1)相差不大;S分别为1.1、1.0、1.0,RERI分别为0.1、-0.1、-0.4,API分别为3.7%、0.0%、-0.4%。当IFN-γ+874 AA、IL-2-330 TT和IL-10-1082 AA三种基因型共存时,感染者不同临床转归类型对应的OR值分别为9.6(2.9~31.8)、12.8 ( 2.0~80.2 )和32.0(5.1~200.9),是IFN-γ+874 AA、IL-2-330 TT共存时OR值的1.3、1.3和3.0倍;S分别为1.1、1.0、2.0,API为4.2%、-0.8%和47.5%,RERI为0.4(0.2~0.7)、-0.1(0.0~0.5)和15.2(3.6~64.3)。
结论:Th1主要细胞因子IFN-γ+874 AA、IL-2-330 TT基因型对慢性HCV/HBV感染者不良临床转归有明显的协同作用;Th2主要细胞因子IL-4-589 CC或CT和IL-10-592 AC基因型对慢性HCV/HBV感染者肝脏炎症性损伤有明显的协同作用;Th1主要细胞因子基因型IFN-γ+874 AA、IL-2-330 TT和Th2主要细胞因子基因型IL-10-1082 AA对慢性HCV/HBV感染者进展为轻型、中重型肝炎交互作用不明显,对进展为肝硬化有协同作用。
Infection with the hepatitis C virus (HCV) and/or hepatitis B virus (HBV) is characterized by a broad spectrum of possible outcomes. Infection is self-limited in a very minority, while the majority of infections develop persistent infection. Among those individuals with persistent HCV and/or HBV infection, the majority develops chronic hepatitis, some progress to fibrosis and even primary hepatocellular carcinoma. The variation may be attributable to viral and host genetic background. However it has been reported that the natural outcome in HCV or HBV infection varies among individuals though infected by the same viral. So there is strong evidence in HCV/HBV infection that host genetic factors play a major role in determining the outcome of infection.
The immunity responses to HCV and HBV infection vary among individuals to a far extent. The single nucleotide polymorphism (SNP) in some cytokines gene greatly influences the clinical outcome of individuals with HCV and HBV infection. Helper T cell (Th) plays a key role in mediated immunity. Th1 cell is produced by the origin of Th in the stimulation of interferon-gamma and Th1 secrete cytokines such as interleukin 2, interferon-gamma, and so on. Th1 cytokines participate in cell-mediated immunity for controlling such intracellular pathogens as viruses, cytotoxic T lymphocyte (CTL) proliferation and activation, and natural killer cells (NK) activation. Th2 cell is produced by the origin of Th with the stimulation of interleukin 4. The major lymphokines secreted by Th2 cell are interleukin 4, interleukin 10 and so on. Th2 cytokines are essential for antibody-mediated immunity by proliferating and activating the B lymphocell. The cytokines from Th1 cells inhibit Th2 cells, and vice versa. The imbalance of Th1 and Th2 heavily disturbed the balance between the cell-mediated immunity and antibody-mediated immunity, which may be the key to the clinical outcome of chronic HCV and/or HBV infection.
There is compelling evidence that cytokines play a significant role in chronic HCV and HBV disease pathogenesis. However, contradictory reports exist as to the exact effect of the cytokines promoter polymorphisms on the natural outcome of HCV and HBV infection. In order to explore the possible association of the cytokines gene polymorphism with the susceptibility of chronic HCV/HBV infection and the outcome of these infections, the IFN-γ+874, IL-2-330, IL-4-589, IL-10-1082, IL-10-592 gene polymorphisms were studied in subjects of mild hepatitis, moderate and severe hepatitis, and cirrhosis infected with HCV, HBV, HCV co-infected with HBV. These results would explore the immune genetic mechanisms of the clinical outcome of HCV and HBV infection.
Part 1 Result comparison of anti-HCV detected by ELISA and HCV RNA detected by RT-n PCR in chronic hepatitis C virus infection
Objective: In order to provide the basis for the clinical test and the blood station screening the health donator, the results of anti-HCV tested by enzyme-linked-immuno-absorbed assay (ELISA) and HCV RNA tested by Reverse-Transcript–nested-Polymerase-Chain-Reaction (RT-n PCR) were compared in the chronic HCV infection.
Methods: Venous blood samples of 133 chronic HCV infections, which were infected with HCV nearly in 1990 through plasma donator and diagnosed in 1993 in a rural area of Zhao County of Hebei Province, and 52 health controls were collected in May 2005. The antibody to HCV was tested by ELISA method and HCV RNA was tested by RT-n PCR method.
Results:①In 185 cases, the rate of both anti-HCV and HCV RNA positive was 49.73% (92/185). The rate of anti-HCV negative but HCV RNA positive was 9.73% (18/185). The rate of anti-HCV positive but HCV RNA negative was 11.89% (22/185). The rate of both anti-HCV and HCV RNA negative was 28.65% (53/185). The result-agreement rate of ELISA and RT-n PCR testing methods was 78.38% ((92+53)/185). Kappa value equals 0.548 (u=8.65, P<0.01). The disagreement rate was not obviously different between ELISA and RT-n PCR testing methods (χ2 paired =0.40, P>0.05), which illustrated high agreement between the ELISA and RT-nPCR methods.②In the diagnosis of chronic HCV infection, the sensitivity of anti-HCV tested by ELISA was 82.71%, the specificity was 92.31%, and the omitting rate was 17.29%. The sensitivity of HCV RNA tested by RT-n PCR was 81.20%, and the specificity was 96.15%, and the omitting rate was 18.80%. The sensitivity was not obviously different between ELISA and RT-n PCR (χ2=0.10,P>0.05).③The sensitivity tested by ELISA parallel with RT-n PCR was 96.75%, which was obviously higher than that of single ELISA (82.71%) (χ2=9.62,P=0.00) and ELISA series with RT-n PCR(χ2=29.39, P=0.00).
Conclusion: The false negative rate was nearly 17% when anti-HCV was used to detect HCV infection. The positive testing rate of HCV infection was increased remarkably when ELISA and RT-n PCR were used simultaneously. Part 2 The study of Th1 cytokine SNP in chronic HCV and/or HBV infection
Objective: To explore the possible association of the polymorphisms in interferon-gamma gene intron 1 at position +874 (IFN-γ+874), interleukin-2 gene at position–330 (IL-2-330) with the susceptibility of HCV and/or HBV infection and the outcome of these infections.
Methods: IFN-γ+874 gene and IL-2-330 gene SNP were detected in 277 subjects including 79 chronic HCV co-HBV infection, 55 individuals only with HCV infection, 69 individuals only with HBV infection and 74 healthy controls, by sequence specific primers-PCR (SSP-PCR) and by restricted fragment long polymorphism-PCR (RFLP-PCR). Hepatocellular injury as suggested by alanine aminotransferase (ALT) was detected by BeckmanLX-20. The presence or absence of viral particles in serum was determined by RT-nPCR. The possible association of the polymorphism of IFN-γ+874, IL-2-330 with the susceptibility of HCV and/or HBV infection and the outcome of these infections were analyzed.
Results:①IFN-γ+874 AA genotype frequency in individuals with chronic HCV, HBV, HCV co-HBV infection was significant higher than that in controls(χ2=16.15,P=0.01). Odds Ratio (OR) and 95% Confidence Interval (95% CI) of IFN-γ+874 AA genotype in chronic infection with HCV, HBV, HCV co- HBV were 3.22 (1.43~7.25), 2.70 (1.24~5.92) and 4.02 (1.88~8.55) compared with TA genotype. No significant differences were found among the HCV, HBV, HCV and HBV infections (P>0.05). There were no significant association of IFN-γ+874 A/T allele frequency with HCV/HBV infections (χ2=4.87, P=0.18); Chronic infection with HCV, HBV, HCV co-HBV was associated with higher IL-2-330 TT genotype frequency (χ2=14.24, P=0.03; OR (95%CI) = 3.46 (1.17~10.20), 7.14 (2.13~23.81), 2.93 (1.15~7.46)) and T allele frequency (χ2=12.33, P=0.01; OR (95%CI)=1.82 (1.09~3.03), 1.73 (1.10~ 2.73), 2.26 (1.39~3.69)). No significant differences were found among the HCV and / or HBV infections (P>0.05).②The outcome of mild chronic hepatitis (CH), moderate/severe CH and cirrhosis during HBV and/or HCV infection was associated with IFN-γ+874 AA genotype (χ2=14.78,P=0.02, OR=3.09 (1.51~6.33), 3.85 (1.70~8.70), 3.14 (1.08~9.17)); No significant relationships were found between IFN-γ+874 A/T allele frequency and the clinical outcome of HBV/HCV infection (χ2=5.68, P=0.13); The outcome of mild CH, moderate/severe CH and cirrhosis during HBV and/or HCV infection was associated with higher IL-2-330 TT genotype frequency (χ2=13.46, P=0.04; OR=3.42 (1.45~8.13), 3.29 (1.10~9.80), 11.11 (1.32~90.91)) and T allele frequency (χ2=11.69, p=0.01; OR=1.83 (1.20~2.80), 1.70 (1.02~2.82), 2.75 (1.32~5.63)), and the IL-2 (-330) GG genotype frequency showed negative correlation with the clinical progression (γ=-0.92, p<0.05).③There were no significant associations of IFN-γ+874 genotype / allele frequency with HCV duplication (χ2=2.36,P=0.31;χ2=1.92,P=0.17). No significant relationship was found between IL-2-330 genotype/allele frequency and HCV duplication (χ2=0.83,P=0.66;χ2=0.20,P=0.66).④There were no significant associations of IFN-γ+874 genotype/allele, IL-2-330 genotype/allele frequency with abnormal ALT (χ2=0.23,P=0.89;χ2=0.12, P=0.74;χ2=1.35,P=0.51;χ2=0.24, P=0.62).
Conclusion: These results suggest that polymorphisms in the IFN-γ+874, IL-2-330 appear to have some influence on the chronic HCV and/or HBV infection, and on the outcome of HCV and/or HBV infections. IFN-γ+874AA, IL-2-330 TT genotype and T allele are possible risk to the chronic HCV and/or HBV infection and to the outcome of HCV and/or HBV infection, however IFN-γ+874 TA, IL-2-330 GG genotype and G allele is possible protective to them.
Part 3 The study of Th2 cytokine SNP in chronic HCV and/or HBV infection
Objective: To explore the possible associations of the polymorphism of interleukin-4 (IL-4) gene at position–589, interleukin-10 (IL-10) gene at position -1082, -592 with the susceptibility of hepatitis C and/or hepatitis B virus infection and the outcome of these infections.
Methods: IL-4-589, IL-10-1082, IL-10-592 gene SNP were detected in 277 subjects including 79 HCV co-HBV infection, 55 individuals only with HCV infection, 69 individuals only with HBV infection and 74 health control, by SSP-PCR and RFLP-PCR. Hepato-cellular injury as suggested by ALT was detected by BeckmanLX-20. The presence or absence of viral particles in serum was determined by RT-nPCR. The possible associations of the polymorphisms of IL-4-589, IL-10-1082 and IL-10-592 with the susceptibility of HCV and/or HBV infection and the outcome of these infections were analyzed.
Results:①Chronic infection with HCV, HBV, HCV co-HBV was not associated with IL-4-589 genotype and allele (χ2=4.41,P=0.62;χ2=0.26,P=0.97); Chronic infection with HCV, HBV, HCV and HBV was associated with higher IL-10-1082 AA genotype frequency (χ2=13.05, P=0.04; OR=2.34 (1.07~5.10), 2.29 (1.10~4.78), 2.56 (1.25~5.21)). However no significant differences were found among the HCV, HBV, HCV and HBV infection (P>0.05). There were no significant association of IL-10-1082 allele frequency among HCV, HBV and HCV co-HBV infections (χ2=4.65,P=0.20).
There were no significant association of IL-10-592 genotype and allele frequency with chronic HBV and/or HCV infection(χ2=2.83,P=0.83;χ2=1.10,P=0.78);②The outcome of mild CH, moderate/severe CH and cirrhosis during HBV and/or HCV infection was associated with IL-10-1082 AA genotype frequency (χ2=11.40, p=0.07; OR=2.03 (1.03~3.98), 2.70 (1.24~5.88), 4.26 (1.59~11.36)), and the IL-10-1082 AA genotype frequency showed positive correlation with the clinical outcome (γ=-0.99, p<0.01), however IL-10-1082 AG genotype frequency showed negative correlation with the clinical outcome (γ=-0.99, p<0.01). There were no significant associations of IL-10-1082 allele frequency, IL-10-592 genotype and allele frequency with HCV/HBV infection and clinical outcome (χ2=5.85, P=0.12;χ2=2.50, P=0.87;χ2=0.92, P=0.82); The outcome of mild CH, moderate/severe CH and cirrhosis during HBV and/or HCV infection was not associated with IL-4-589 genotype and allele frequency (χ2=4.58, P=0.60;χ2=2.46, P=0.48).③There were obviously associations of IL-10-1082 higher AA genotype frequency and A allele frequency with HCV replication (χ2=12.27, P=0.00;χ2=5.36, P=0.02). The risk of subjects with AA genotype or A allele was 3.36 times (1.67~6.76), 1.67 times (1.08~2.57) than that with AG genotype and G allele; There were no significant associations of IL-10-592, IL-4-589 genotype/allele frequency with HCV replication (χ2=2.10, P=0.35;χ2=1.88, P=0.17;χ2=1.53, P=0.47;χ2=1.24, P=0.27).④There were no significant associations of IL-10-1082 genotype and allele frequency and IL-10-592 allele frequency with abnormal ALT (χ2=3.25, P=0.20;χ2=1.79, P=0.18;χ2=2.30, P=0.13); Abnormal ALT level was associated with higher IL-10-592 AC genotype (χ2=6.32, P=0.04; OR=2.83(1.26~6.37)); Abnormal serum ALT level was associated with IL-4-589 CC and CT genotype (χ2=12.46, P=0.00; OR=8.25 (1.74~ 39.22), 3.43 (1.47~8.00)) and the C allele (χ2=9.97, P=0.00, OR=2.31 (1.36~3.93)).
Conclusion: These results suggest that polymorphism in the IL-10-1082 appears to have some influence on the chronic HCV and/or HBV infection, and on the outcome of HCV and/or HBV infections and HCV replication. IL-10-1082 AA genotype is possible risk to the chronic HCV, HBV and HCV co-HBV infection and the clinical outcome, however AG genotype is possible protective to them. IL-10-592 AC genotype frequency has influence on the liver damage, and IL-4-589 CT, CC genotype, and C allele are possible risk to the liver inflammatory injury, and TT genotype and T allele is possible protective to it.
Part 4 The interaction of Th1 and Th2 cytokine SNP in the clinical outcome infected with chronic HCV and/or HBV
Objective: To analyze the interaction of the Th1 and Th2 cytokine SNP in HCV/HBV infection and in the outcome of these infections. Methods: The interaction of the Th1 and Th2 cytokine SNP in HCV and/ or HBV infection and the outcome of these infections was analyzed by multifactor dimensionality reduction (MDR). The OR was used to evaluate the risk of clinical outcome during HCV/HBV infection. The synergy index (S), Attributable proportion of interaction (API), Relative excess risk of interaction (RERI) and 95% CI were used to evaluate the interaction degree.
Results:①The interaction of IFN-γ+874 AA and IL-2-330 TT genotype was found in the clinical outcome of chronic HCV/HBV infection by MDR (P=0.00). When individuals carried with IFN-γ+874 AA genotype and IL-2-330 TT genotype, the OR and 95% CI for the HCV/HBV to develop to mild CH, moderate/severe CH and cirrhosis was 10.1(2.8~36.0), 10.6(2.9~38.8) and 13.6(4.9~66.8) respectively, and the OR in individuals with IFN-γ+874 AA and IL-2-330 TT was 6.8 times, 4.1 times and 6.6 times compared with individuals of only IFN-γ+874 AA, and was 8.4 times, 8.1 times and 6.6 times comparied with individuals of only. The S of chronic HCV/HBV infection developing to mild CH, moderate/severe CH and cirrhosis in IFN-γ+874 AA and IL-2-330 TT genotype was 13.04, 5.01 and 7.22 respectively. RERI and 95% CI were 8.43(2.61~27.23), 7.65(2.50~23.42) and 10.83(2.53~46.32). API was 83.22%, 72.44% and 79.81% respectively.②Interaction of IL-10-592 gene and IL-4-589 gene was found in the hepato-cellular injury of chronic HCV and / or HBV infection by MDR (P=0.00). When only with IL-10-592 AC, there was no significant effect on the hepato-cellular injury of chronic HCV/HBV infection (OR=1.0). However together with IL-4-589 CC or CT and IL-10-592 AC, the OR was 5.5 (2.6~11.5). It was found to have significant interaction to the hepato-cellular injury, which the S was 7.1, RERI was 3.7(2.11~6.49), and API was 67.6%.③The interaction of IFN-γ+874 gene, IL-2-330 gene and IL-10-1082 gene was found in the clinical outcome of chronic HCV/HBV infection by MDR (P=0.01). When one SNP were analyzed, the IL-10-1082 AA genotype had the highest risk (OR=2.7, 4.3, 7.1), IFN-γ+874 AA genotype had the middle risk (OR=2.0, 3.9, 2.4), IL-2-330 TT had the lowest risk (OR=1.2, 1.3, 2.8) to the outcome of HCV/HBV infection. The IL-10-1082 AA genotype was positive correlation with the clinical progression (γ=0.99, P<0.05). When two SNP were analyzed at a time, IFN-γ+874 AA genotype and IL-2-330 TT genotype had a high risk for the HCV/HBV to develop to mild CH, moderate/severe CH and cirrhosis, OR=7.5(2.0~28.4), 9.6(2.6~35.6) and 10.7(1.4~ 80.2)), which were not equal to the OR=10.1(2.8~36.0), 10.6(2.9~38.8) and 13.6(4.9~66.8) of IFN-γ+874 AA genotype and IL-2-330 TT genotype was due to with or without considering the interaction of IL-10-1082 AA genotype. The risk of both IFN-γ+874 AA genotype and IL-2-330 TT genotype in mild CH, moderate/severe CH and cirrhosis was 3.8 times, 2.5 times and 4.5 times comparied with only IFN-γ+874 AA genotype, and was 6.3 times, 7.4 times and 3.8 times comparied with only IL-2-330 TT genotype. The S was 5.3, 2.7 and 3.0 respectively , the RERI was 5.25(1.1~24.5), 5.41(1.8~16.2) and 6.5(1.3~31.5), the API was 70.28%, 56.35%, 60.54%. When together with IFN-γ+874 AA genotype and IL-10-1082 AA genotype, the OR in mild CH, moderate/severe CH and cirrhosis was 1.6(1.0~2.5), 4.0(1.6~9.9) and 5.3(1.5~ 19.1) respectively, which was lower than that with only IL-10-1082 AA genotype. The S was 0.22, 0.49, 0.58 respectively, the RERI was -2.1(-1.1~-4.1), -3.2(-1.5~ -6.8), -3.15 (-1.3~ -7.6) respectively, the API was -130.00%, -79.50%, -59.10% respectively. When together with IL-2-330 TT genotype and IL-10-1082 AA genotype, the OR in mild CH, moderate/severe CH and cirrhosis was 3.0(1.3~7.2), 4.5(1.6~12.3), 8.5(2.0~35.7), which was similar to the OR of only with IL-10-1082 AA genotype. S was 1.06, 0.98, 0.95 respectively, RERI was 0.11, -0.07, -0.42, API was 3.68%, -0.02%, -0.42%. When three SNPs were analyzed at a time, OR in mild CH, moderate/severe CH and cirrhosis was 9.6(2.9~31.8), 12.8(2.0~80.2) and 32.0(5.1~200.9). The OR was the 1.3 times, 1.3 times and 3.0 times compared with IFN-γ+874 AA and IL-2-330 TT. S was 1.1, 1.0 and 2.0, API was 4.2%, -0.8% and 47.5%, RERI was 0.4(0.2~0.7), -0.1(0.0~0.5) and 15.2(3.6~64.3) respectively.
Conclusion: These results suggest that subjects with IFN-γ+874 AA genotype and IL-2-330 TT genotype had higher risk for the clinical outcome of chronic HCV/HBV infection, the subjects with IL-10-592 AC genotype and IL-4-589 CC or CT genotype had a higher risk for the hepato-cellular injury of chronic HCV/HBV infection. IFN-γ+874 AA and IL-2-330 TT together with IL-10-1082 AA had no significant interaction for HCV/HBV infection to the mild CH, moderate and severe CH, however had positive interaction for HCV/HBV infection develop to cirrhosis.
引文
1 Kim WR. The burden of hepatitis C in the United States. Hepatology, 2002, 36(5S): 30~34
2 Roffi L, Redaelli A, Colloredo G, et al. Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype. Eur J Gastroenterol Hepatol, 2001, 13(5): 501~506
3 Degos F. Natural history of hepatitis C virus infection. Nephrol- dial- transplant, 1996, 11(S4): 16~18
4 文汉成,安社刚,张红芳.抗-HCV 与 HCV-RNA 检测结果不一致原因分析.实用医技杂志,2004,11(8):1707~1708
5 王良华,吴国光,陈刚.荧光定量PCR检测血液中的丙型肝炎病毒(HCV).中国输血杂志,2001,14(S):133
6 中华医学会传染病与寄生虫病学分会、肝病学分会联合修订.病毒性肝炎防治方案.中华传染病杂志,2001,19(1):56~62
7 吴昌烈,郑岚,冯恭文,等.全国血站检验的室间质量评价.中国输血杂志,1997,10(1):51
8 赵继义,刘雪梅,郭薇媛,等.RT 套式 PCR 检测血浆 HCV RNA 及与抗 HCV检测的比较.微生物学杂志,2001,21(4):37~38
9 王乐斌,赵久法.抗-HCV 阴性献血员丙肝病毒感染及意义.临床医学,2000,25(6):442
10 Cieslak PR, Hedberg K, Thomas AR, et al. Hepatitis C virus transmission from an antibody-negative organ and tissue donor---United States. Morb Mortal Wkly Rep, 2003, 52(3):273~276
11 Willems M, Metselaar HJ, Tilanus HW, et al. Liver transplantation and hepatitis C. Transpl Int, 2002; 15(1): 61~72
12 潘宁,张建琼,李丽,等.应用荧光定量 PCR 检测血清中 HCV RNA.东南大学学报(医学版),2003,22(1):16~18
13 王平忠,白雪帆,傅恩清,等.不同基因型丙型肝炎病毒RNA定量分析.第四军医大学学报,2002,23(17):1548~1550
14 魏来,王齐欣,徐小元,等.河北省固安县某农村单采浆献血员丙型肝炎病毒感染的追踪研究.北京大学学报(医学版),2002,34(5):574~578
1 Roffi L, Redaelli A, Colloredo G, et al. Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype. Eur J Gastroenterol Hepatol, 2001, 13(5): 501~506
2 Pan CQ, Zhang JX. Natural History and Clinical Consequences of Hepatitis B Virus Infection. Int J Med Sci, 2005, 2(1):36~40
3 Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community acquired hepatitis C in the United States. N Engl J Med. 1992, 327(27):1899~1905
4 Seder RA, Paul WE. Acquisition of lymphokine-producting phenotype by CD4+ T cells. Annu Rev Immunol, 1994, 12(2):635~674
5 Osna N, Silonova G, Vilgert N, et al. Chronic hepatitis C: T-helper1 / T-helper2 imbalance could cause virus persistence in peripheral blood. Scand J Clin Lab Invest, 1997, 57(8):703~710
6 Paul S, Tabassum S, Islam MN. Interferon- gamma (IFN-gamma) response to different hepatitis B virus antigens in hepatitis B virus infection. Bangladesh Med Res Counc Bull, 2004, 30(2):71~77
7 Pravica V, Perrey C, Stevens A, et al. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Hum Immunol, 2000, 61(9):863~866
8 张平安,吴健民,李艳.IFN-γ基因+ 874 位点单核苷酸多态性与乙型肝炎病毒感染关系的研究.医学临床研究,2005,22(9):1189~1192
9 Pawlowska M, Bishop GA, McGuinness PH, et al. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology, 1996, 24(4):759~765
10 Napoli J, Bishop GA, McGuinness PH, et al. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology, 1996, 24(4): 759~765
11 中华医学会传染病与寄生虫病学分会、肝病学分会联合修订.病毒性肝炎防治方案.中华传染病杂志,2001,19(1):56~62
12 Belardelli F. Role of interferon and other cytokines in the regulation of the immune response. APMIS, 1995, 103(3):161~179
13 Muller U, Steinhoff U, Reis L, et al. Functional role of typeI and type II interferons in antiviral defense. Science, 1994, 264(5167):1918~1921
14 Zhang P, Chen Z, Chen F, et al. Expression of IFN-γ and its receptor alpha in the peripheral blood of patients with chronic hepatitis C. ChineseMedical Journal, 2004, 117(1):79~82
15 Bertoletti A, D'Elios MM, Boni C, et al. Different cytokine profile of intrahepatic T cells in chronic hepatitis B and hepatitis C virus infection. Gastroenterology, 1997, 112(1):193~199
16 Zhao CY, Liu JX, Tang HH, et al. Significance of IL-2 and related indexes in patients with hepatitis and hepatocellular carcinoma. World Chinese Journal of digestion, 1998, 6 (6):479~481
17 Eckels DD, Tabatabail N, Bian TH, et al. In vitro human Th-cell responses to a recombinant hepatitis C virus antigen: Failure in IL-2 production despite proliferation. Hum Immunol, 1999, 60(3):187~199
18 Pawlowska M, Halota W, Smukalska E, et al. Serum IL-2 and sIL-2R concentrations in children with chronic hepatitis B. Pol Merkur Lekarski, 2005, 18(103): 33~35
1 Roffi L, Redaelli A, Colloredo G, et al. Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype. Eur J Gastroenterol Hepatol, 2001, 13(5): 501~506
2 DegosF. Natural history of hepatitis C virus infection. Nephrol- dial-transplant, 1996, 11(S4): 16~18
3 Pan CQ, Zhang JX. Natural History and Clinical Consequences of Hepatitis B Virus Infection. Int J Med Sci, 2005, 2(1): 36~40
4 Cecile G, Heiene C, Jerome C, et al. Lethal Hepatitis After Gene Transfer of IL-4 in the Liver Is Independent of Immune Responses and Dependent on Apoptosis of Hepatocytes: A Rodent Model of IL-4-Induced Hepatitis. The Journal of Immunology, 2001, 166(8): 5225~5235
5 章仕坚,朱宁,林智强,等.各型 HBV 感染中白介素-12、白介素-4 的测定及意义.暨南大学学报(医学版),2004, 25(2):224~226
6 Gramenzi A, Andreone P, Loggi E, et al. Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. Journal of Viral Hepatitis, 2005, 12 (5): 525~530
7 Rosenwasser LJ, Klemm DJ, Dresback JK, et al. Promotor polymorphisms in the chromosome 5 gene cluster in asthma and atopy. Clin Exp Allergy, 1995, 25(S2): 74~78
8 Zhang P, Chen Z, Chen F, et al. Expression of IFN-γ and its receptor alpha in the peripheral blood of patients with chronic hepatitis C. Chinese Medical Journal, 2004, 117(1): 79~82
9 Jia HY, Du J, Zhu SH, et al. Clinical observation of serum IL-18, IL-10 and sIL-2R levels in patients with chronic hepatitis C pre- and post antiviral treatment. Chinese Medical Journal, 2003, 116(4): 605~608
10 Cacciarelli TV, Martinez OM, Gish RG, et al. Immunoregulatory cytokines in chronic hepatitis C virus infection: Pre- and posttreatment with interferon alfa. Hepatology, 1996, 24(1): 6~9
11 Domenico L, Calogero C, Rosa DS, et al. IL-10 and TNF-α Polymorphisms and the Recovery from HCV Infection. Human Immunology. 2003, 64(7): 674~680
12 Vidigal PG, Germer JJ, Zein NN. Polymorphisms in the interleukine-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 gene in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol, 2002, 36(2): 271~277
13 Groux H, Bigler M, de Vries JE, et al. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J Immunol, 1998, 160(7): 3188~3193
14 Vercelli D, Dc Montc L, Monticelli S, et al. To E or not to E? Can an IL-4-induced B cell choose between IgE and IgG4? Int Arch Allergy Immunol, 1998, 116(1): 1~4
15 Turner DM, Williams DM, Sankaran D, et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet, 1997, 46(2): 120~128
16 Peng XM, Huang YS, Ma HH, et al. Interleukin-10 promoter polymorphisms are associated with the mode and sequel of HBeAg seroconversion in patients with chronic hepatitis B virus infection. Liver International, 2006, 26(3): 326~333
17 Shin HD, Park BL, Kim LH, et al. Common interleukin 10 polymorphism associated with decreased risk of tuberculosis. Experimental and Molecular Medicine, 2005, 3(2): 128~132
18 Powell EE, Edwards-Smith CJ, Hay JL, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology, 2000, 31(4): 828~833
19 Barrett S, Collins M, Kenny C, et al. Polymorphisms in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection. J Med Virol, 2003, 71(2): 212~218
20 Cribier B, Schmitt C, Rev D, et al. Porduction of cytokines in patients by hepatitis C virus. J Med Virol, 1998; 55(2): 89~91
21 Kato A, Yoshidome H, Edwards MJ, et al. Reduced hepatic ischemia / reperfusion injury by IL-4: potential anti-inflammatory role of STAT6. Inflammation Res, 2000, 49(6): 275~279
22 Yoshidome H, Kato A, Miyazaki M, et al. IL-13 activates STAT6 and inhibits liver injury induced by ischemia/reperfusion. Am J Pathol, 1999, 155(4): 1059~1064
1 赵根明. 交互作用. 见:李立明, 主编. 临床流行病学.北京: 人民卫生出版社,2002, 143~159
2 Roffi L, Redaelli A, Colloredo G, et al. Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype. Eur J Gastroenterol Hepatol, 2001, 13(5): 501~506
3 Pan CQ, Zhang JX. Natural History and Clinical Consequences of Hepatitis B Virus Infection. Int J Med Sci, 2005, 2(1): 36~40
4 Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community acquired hepatitis C in the United States. N Engl J Med. 1992, 327(27): 1899~1905
5 Romagnani S. The Th1/Th2 paradigm. Immunol Today, 1997, 18(6): 263~266
6 Gramenzi1 A, Andreone1 P, Loggi1 E, et al. Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. J Viral Hepatitis, 2005, 12(5): 525~534
7 Bozkaya H, Bozdayi M, Turkyilmaz R, et al. Circulating IL-2, IL-10 and TNF-alpha in chronic hepatitis B: their relations to HBeAg status and the activity of liver disease. Hepatogastroenterology, 2000, 47(36): 1675~1679
8 Moore JH. The ubiquitous nature of epistasis in determing susceptibility to common human diseases. Hum Hered, 2003, 56(1): 73~82
9 Moore JH, Ritchie MD. The challenges of whole-genome approaches to common diseases. JAMA, 2004, 291(13): 1642~1643
10 Ritchie MD, Hahn LW, Roodi N, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet, 2001, 69(1): 138~147
11 Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interaction. Bioinformatics, 2003, 19(3): 376~382
12 唐迅, 李娜, 胡永华. 应用多因子降维化分析基因-基因交互作用. 中华流行病学杂志.2006,27(5): 437~441
13 Rothman KJ. Epidemiology: an introduction. Oxford, United Kingdom: Oxford University Press, 2002
14 Barrett S, Collins M, Kenny C, et al. Polymorphisms in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection. J Med Virol, 2003, 71(2): 212~218
15 Paul S, Tabassum S, Islam MN. Interferon- gamma (IFN-gamma) response to different hepatitis B virus antigens in hepatitis B virus infection. Bangladesh Med Res Counc Bull, 2004, 30(2): 71~77
16 陈显兵.Th1/Th2 漂移与 HCV 感染慢性化.国际免疫学杂志,2006;29(1): 51~54
1 Kim WR. The burden of hepatitis C in the United States. Hepatology, 2002, 36(5S): 30~34
2 Degos F. Natural history of hepatitis C virus infection. Nephrol Dial Transplant, 1996, 11(S4): 16~18
3 Tran TT, Martin P. Hepatitis B: epidemiology and natural history. Clin Liver Dis, 2004, 8(2): 255~266
4 Kotwal GJ, Baroudy BM, Kuramoto IK, et al. Detection of acute hepatitis C virus infection by ELISA using a synthetic peptide comprising a structural epitope. Proc Natl Acad Sci USA, 1992, 89(10): 4486~4489
5 杨东亮.丙型肝炎的病毒学检测指标及其临床意义.中华肝脏病杂志,2004,12(2):104
6 吴昌烈,郑岚,冯恭文,等.全国血站检验的室间质量评价.中国输血杂志,1997,10(1):51
7 文汉成,安社刚,张红芳.抗-HCV 与 HCV-RNA 检测结果不一致原因分析.实用医技杂志, 2004, 11(8):1707~1708
8 王良华,吴国光,陈刚.荧光定量PCR检测血液中的丙型肝炎病毒(HCV).中国输血杂志,2001,14(S):133
9 王乐斌,赵久法.抗-HCV 阴性献血员丙肝病毒感染及意义.临床医学,2000,25(6):442
10 Centers for Disease Control and Prevention (CDC). Hepatitis C virus transmission from an antibody-negative organ and tissue donor in United States. Morb Mortal Wkly Rep, 2003, 52(13): 273~274
11 Willems M, Metselaar HJ, Tilanus HW, et al. Liver transplantation and hepatitis C. Transpl Int, 2002; 15(2-3): 61~72
12 Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology, 2002, 36(S): 65~73
13 庄辉.重视丙型肝炎的研究.中华肝脏病杂志,2004, 12(2): 65~66
14 邢文革,郑怀竞.必须提高丙型肝炎病毒实验室检验结果的可信度. 中华肝脏病杂志,2004,12(3):170~171
15 Ballardini G, Groff P, Giostra F, et al. Hepatocellular codistribution of c100, c33, c22, and NS5 hepatitisC virus antigens detected by using immunopurified polyclonal spontaneous human antibodies. Hepatology, 1995, 21(5): 730~734
16 Pasquier C, Bujan L, Daudin M, et al. Intermittent detection of hepatitis C virus (HCV) in semen from men with human immunodeficiency virus type 1(HIV-1) and HCV. J Med Virol, 2003, 69(3): 344~349
17 陈佩兰,李琳,田惠英,等.丙型肝炎患者外周血单个核细胞 HCV 和 Fas抗原检测.军医进修学院学报,2000,21(3):215~217
18 Kashiwakuma T, Hasegawa A, Kajita T, et al. Detection of hepatitis C virus specific core protein in serum of patients by a sensitive fluorescence enzyme immunoassay. J Immunol Methods, 1996, 190(1): 79~89
19 Cano H, Candela MJ, Lozano ML, et al. Application of a new enzyme linked immuno sorbent assay for detection of total hepatitis C virus core antigen in blood donors. Transfus Med, 2003, 13(5): 259~266
20 Peterson J, Green G, Lida K, et al. Detection of hepatitis C core antigen in the antibody negative “window” phase of hepatitis C infection. VoxSang, 2000, 78(2): 80~85
21 Lee SR, Peterson J, Niven P, et al. Efficacy of a hepatiits C virus core antigen enzyme linked immuno sorbent assay for the identification of “window phase” blood donations. VoxSang, 2001, 80(1): 19~23
22 Courouce AM, Marrec NL, Bouchardeau F, et al. Efficacy of HCV core antigen detection during the preseroconversion period. Transfusion, 2000, 40(10): 1198~1202
23 Aoyagi K, Ohue C, Lida K, et al. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J Clin Microbiol, 1999, 37(6): 1802~1808
24 Lunel F, Veillon P, Payan C. Evaluation of the Ortho total HCV core antigen assay in comparison to methods of detection and quantification for HCV RNA. Hepatology, 2002; 36(2): 353~357
25 Maynard M, Buti M, Esteban JI, et al. High clinical relevance of total HCVcore antigen testing for monitoring and predicting response to PEG-IFN / ribavirin combination therapy. Hepatology, 2002; 36(2): 359~363
26 Darius M, Takaji W, Tokushige K, et al. Characterization of three novel monoclonal antibodies against hepatitis C virus core protein. J Med Virol, 1996, 48(3): 234~241
27 郭满盈,李谋深,李保仝,等. 献血者血清中 HCV NS3 和核心蛋白抗原的检测及临床意义.中国输血杂志,2001,14(2):78~79
28 中华医学会肝病学分会、中华医学会传染病与寄生虫病学分会.丙型肝炎防治指南.中华流行病学杂志,2004,25(5):369~375
29 吴文娟.HBVe 抗原抗体检测准确性分析.贵州医药,2002,26(5):470
30 赵勇,周影.用PCR技术检测50名HBsAg阴性献血者血清HBV-DNA结果.中国输血杂志,1996,6(4):214
31 安萍,李世拥,韩玲霞,等.PCR 直接法检测 HBsAg 阴性肝病的价值.新消化病学杂志,1996,4(7):385
32 骆抗先,何超,周荣,等.聚合酶链反应对单一抗 HBc 阳性的乙型肝炎病毒携带者的检测.中华医学杂志,1992,72(1):11
33 胡庆宏,刘明跬,陈奕东,等.荧光定量 PCR 在乙型肝炎病毒检测中的应用及临床意义.江西医学院学报,2003,43(4):38~40
34 Brunetto MR, Randone A, Ranki M, et al. Quqntitative analysis of wild type and HbeAg minus hepatitis B viruses by a sequence dependent primer extension assay. J Med Virol, 1994, 43(3): 310~315
35 Hwang SJ, Lu RH, Wood ML, et al. Comparison of the nucleic acid based cross linking hybridization assay and the branched DNA signal amlification assay in the quantitative measurement of serum hepatitis B virus DNA. J Clin Lab Anal, 1999,13(6): 296~300
36 Nolte FS. Branched DNA signal amplification ofr direct quantitation of nucleic acid sequences in clinical specimens. Adv Clin Chem, 1998, 33(2): 201~235
37 Krajden M, Minor JM, Rifkin O, et al. Effect of multiple freeze thaw cycleson hepatitis B virus DNA and hepatitis C virus RNA quantification as measured with branched DNA technology. J Clin Microbiol, 1999, 37(6):1683~1686
38 Hendricks DA, Stowe BJ, Hoo BS, et al. Quantitation of HBV DNA in human serum using a branched DNA (b DNA) signal amplification assay. Am J Clin Pathol, 1995, 104(5): 537~546
39 Jardi R, Buti M, Cotrina M, et al. Quantitative determination of HBV DNA in chronic hepatiits B: comparison of three methods. Gastroenterol Hepatol, 1998, 21(7): 327~331
40 黄建宏,欧兴义,梁小兵,等.乙型肝炎病毒 DNA 检测及其与血清标志物的关系探讨.实用诊断与治疗杂志,2005,19(1):4~5
41 范火亮.乙型肝炎病毒感染者 HBVDNA 与血清病毒标志物的关系.中国基层医药, 2006, 13(1): 64~65
42 Chen RW, Piiparinen H, Seppanen M, et al. Real-time PCR for detection and quantitation of HBV DNA. J Med Virol, 2001,65(2): 250~256
43 Pawlowsky JM, Bastie A, Hezode C, et al. Routine detection and quantification of HBV DNA in clinical laboratories: performance of three commercial assays. J Virol Methods, 2000, 85(1): 11~21
44 陈晓东,陶志华,周武.核酸提取方法在聚合酶链反应测定乙肝病毒核酸中的评价.中华检验医学杂志,2002,25(4):212~214
45 Kimura T, Pokuhara A, Matsumoto A, et al. New Enzyme Immunoassay for Detection of Hepatitis B Virus Core Antigen (HBcAg) and Relation between Levels of HbcAg and HBV DNA. J Clin Microbiology, 2003,41(5): 1901~1906
46 王厚照,田丰丰,陆金霞,等. ELISA 检测乙肝病毒核心抗原的方法建立及应用.中华乙肝防治指南网, 2007.3.5
47 Delfini C, Colloca S, Taliani G, et al. Clearance of hepatitis B virus DNA and pre-S surface antigens in patients with markers of acute viral replication. J Med Virol, 1989,28(2): 169~175
48 张雪红,易长庚,喻淑萍.乙肝患者血清前 S1 蛋白与 HBV-M、HBV-DNA检测结果的分析.中国医师杂志, 2005, 7(1):137~137
49 Yuki N,Hayashi N,Katayama K,et al. Quantitative analysis of Pre-S1 and Pre-S2 in relation to HBsAg expression. Hepatology, 1990, 11(1):38~40
1 Roffi L, Redaelli A, Colloredo G, et al. Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype. Eur J Gastroenterol Hepatol, 2001, 13(5): 501~506
2 Pan CQ, Zhang JX. Natural History and Clinical Consequences of Hepatitis B Virus Infection. Int J Med Sci, 2005, 2(1): 36~40
3 Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community acquired hepatitis C in the United States. N Engl J Med, 1992, 327(27): 1899~1905
4 Tong MJ, Farra NS, Reikes AR, Cl RL. Clinical outcomes after transfusion-associated hepatitis C (see comments). N Engl J Med, 1995, 332(22): 1463~1466
5 Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol, 1999, 31 [S1]: 9~16
6 Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology, 1997, 26(S3): 15~20
7 Poyanard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet, 1997, 349 (9055): 825~832
8 Kenny Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med, 1999, 340(16): 1228~1233
9 Nishimura T, Ohta A. A critical role for antigen-specific Th1 cells in acute liver injury in mice. J Immunol, 1999, 162(11): 6503~6509
10 Rossl S, Marinos G, Caruccl P, et al. Interleutin-12 inducation of Th1 cytokines is impotant for virus clearance in chronic hepatitis B. J Clin Invest, 1997, 99(12): 3025~3033.
11 Weigent DA, Stanton GJ, Johnson HM. Interleukin 2 enhances natural Killer cell activity through induction of gamma interferon. Infect Immun, 1983, 41(3): 992~997
12 Hoffmann SC, Stanley EM, Darrin Cox E, et al. Association of cytokine polymorphic inheritance and in vitro cytokine production in anti- CD3/CD8 -stimulated peripheral blood lymphocytes. Tranplantation, 2001, 72(8): 1444~1452
13 Missale G, Ferrari C, Fiaccadori F. Cytokines mediators in acute inflammation and chronic course of viral hepatitis. Ann Ital Med Int, 1995, 10(1): 14~18
14 Castillo FM, Romero TA, Estevez J, et al. Concentrations of Cytokines, Soluble Interleukin-2 Receptor, and Soluble CD30 in Sera of Patients with Hepatitis B Virus Infection during Acute and Convalescent Phases.Clinical and Diagnostic Laboratory Immunology, 2002, 9(6): 1372~1375
15 Bozkaya H, Bozdayi M, Turkyilmaz R, et al. Circulating IL-2, IL-10 and TNF-alpha in chronic hepatitis B: their relations to HBeAg status and the activity of liver disease. Hepatogastroenterology, 2000,47(36):1675~1679
16 Napoli J, Bishop GA, McGuinness PH, et al. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology,1996, 24(4):759~765
17 Chevillard C, Henri S, Stefani F, et al. Two new polymorphisms in the human interferon gamma (IFN-gamma) promoter. Eur J Immunogenet, 2002, 29(1): 53~56
18 Pravica V, Perrey C, Stevens A, et al. A single nucleotide polymorphism in the first intron of the human IFN-γ gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-γ gene. Hum Immunol, 2000, 61(9):863~866
19 Henri S, Stefani F, Parzy D, et al. Description of three new polymorphisms in the intronic and 3’UTR regions of the human interferon gamma gene. Genes Immun, 2002, 3(1):1~4
20 Lio D, Scola L, Crivello A, et al. Allele frequencies of -874T/A single nucleotide polymorphism at the first intron of interferon-gamma gene in a group of Italian centenarians. Exp Gerontol, 2002, 37(2-3): 315~319
21 Bidwell J, Keen L, Gallagher G, et al. Cytokine polymorphism in human disease. Genes Immun, 2001, 2(1): 61~70
22 张平安,吴健民,李艳.干扰素-γ 基因内含子 1+874 位点多态性与乙型肝炎病毒感染关系的研究.中华流行病学杂志, 2006, 27(1): 41~43
23 Ben Ari Z, Mor E, Papo O, et al. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol. 2003, 98(1): 144~150
24 俞蕙,朱启镕,顾绍庆,等. IFN-γ+874 基因单核苷酸多态性与宫内 HBV感染易感性关系的研究.中华儿科杂志, 2004,42(6):421~423
25 贾因棠,魏来,蒋栋,等.干扰素-γ对丙型肝炎病毒复制子的抑制作用.中华肝脏病杂志, 2006,14(1):7~10
26 Thimme R, Bukh J, Spangenberg HC, et al. Viral and immunological determinants of hepatitis C virus clearance,persistence and disease. Proc Natl Acad Sci USA, 2002, 99(24): 15661~15668
27 Zhang P, Chen Z, Chen F, et al. Expression of IFN-γ and its receptor alpha in the peripheral blood of patients with chronic hepatitis C. Chinese Medical Journal, 2004, 117(1): 79~82
28 路文明,曹文贵.慢性丙型肝炎患者血清 IL-6、IFN-γ的检测意义.肝脏,2002:7(4): 287~288
29 Ben-Ari Z, Pappo O, Druzd T, et al. Role of cytokine gene polymorphism and hepatic transforming growth factor beta1 expression in recurrent hepatitis C after liver transplantation. Cytokine, 2004, 27(1): 7~14
30 Dai CY, Chuang WL, Hsieh MY, et al. Polymorphism of interferon–gamma gene at position-874 and clinical characteristics of chronic hepatitis C. Translational Research, 2006, 148(3): 128~133
31 Cecile G, Heiene C, Jerome C, et al. Lethal Hepatitis After Gene Transfer of IL-4 in the Liver Is Independent of Immune Responses and Dependent on Apoptosis of Hepatocytes: A Rodent Model of IL-4-Induced Hepatitis. The Journal of Immunology, 2001, 166(8): 5225~5235
32 Lohr H F,SchlaakJ FG,Gerken B, et al. Phenotypical analysis and cytokine release of liver-infiltrating and peripheral blood T lymphocytes from patients with chronic hepatitis of different etiology. Liver, 1994, 14(2): 161~166
33 Martinez OM, Villanueva JC, Greshwin E, et al. Cytokine patterns and cytotoxic mediators in primary biliary cirrhosis. Hepathology, 1995, 21(1): 113~119
34 Rosenwasser LJ, Klemm DJ, Dresback JK, et al. Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy. Clin Exp Allergy,1995, 25(S):74~78
35 章仕坚,朱宁,林智强,等.各型 HBV 感染中白介素-12、白介素-4 的测定及意义.暨南大学学报(医学版), 2004, 25(2): 224~226
36 王坤,时昌文,高勇,等.中国北方两市部分人群 IL-2、IL-4 基因多态性 与 乙 肝 关 联 性 的 研 究 . 中 国 现 代 普 通 外 科 进展,2006,11(3):117~123
37 朱启镕,顾绍庆,俞惠,等.细胞因子基因多态性与乙型肝炎病毒宫内感染易感性的研究.中华流行病学杂志,2005,26(4):236~239
38 Gramenzi A, Andreoe P, Loggi E, et al. Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. Journal of Viral Hepatitis,2005,12(5): 525~534
39 Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin –6 transcriptional regulation. J Biol Chem, 2000, 275(24):18138~18144
40 Park BL, Lee HS, Kim YJ, et al. Association between interleukin 6 promoter variants and chronic hepatitis B progression. Exp Mol Med, 2003, 35(2): 76~82
41 Barrett S, Collins M, Kenny C, et al. Polymorphisms in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection. J Med Virol, 2003, 71(2): 212~218
42 Gibbs VC, Pennica D. CRF2-4: isolation of cDNA clones encoding the human and mouse proteins. Gene, 1997, 186(1): 97~101
43 Im SH, Hueber A, Monticelli S, et al. Chromatin-level regulation of the IL10 gene in T cells. J Biol Chem, 2004, 279(45): 46818~46825
44 Moore KW, de Waal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol, 2001, 19(4): 683~765
45 Ito S, Ansari P, Sakatsume M, et al. Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma- induced genes by suppressing tyrosine phosphorylation of STAT1. Blood, 1999, 93(5): 1456-1463
46 Nelson DR, Lauwers GY, Lau JY, et al. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology, 2000, 118(4): 655~660
47 Louis H, Le Moine O, Peny MO, et al. Production and role ofinterleukin-10 in concanavalin A-induced hepatitis in mice. Hepatology, 1997, 25(6): 1382~1389
48 Louis H, Van Laethem JL, Wu W, et al. Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice. Hepatology, 1998, 28(6): 1607~1615
49 Edwards-Smith CJ, Jonsson JR, Purdie DM, et al. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology, 1999; 30(2): 526~530
50 Thompson K, Maltby J, Fallowfield J, et al. Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis. Hepatology, 1998, 28(6): 1597~1606
51 Turner DM, Williams DM, Sankaran D, et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet, 1997, 24(1): 1~8
52 Miura Y, Thoburn CJ, Bright EC, et al. Cytokine and chemokine profiles in autologous graft-versus-host disease (GVHD): interleukin 10 and interferon gamma may be critical mediators for the development of autologous GVHD. Blood, 2002, 100(7): 2650~2658
53 Eskdale J, Gallagher G, Verweij CL, et al. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA, 1998, 95(16): 9465~9470
54 Mangia A, Santoro R, Piattelli M, et al. IL-10 haplotypes as possible predictors of spontaneous clearance of HCV infection. Cytokine, 2004, 25(3): 103~109
55 Miyazoe S, Hamasaki K, Nakata K, et al. Influence of interleukine-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus. Am J Gastroenterol, 2002, 97(8): 2086~ 2092
56 吴晓蔓, 郭海波.慢性乙型肝炎患者血清 IL-10 与 HBVDNA 复制水平检测及临床意义. 临床肝胆病杂志, 2004, 20(3): 151~152
57 张萍,颜学兵,吴文漪,等.慢性乙型肝炎患者外周血单个核细胞 Th1、T型细胞标志物及其细胞因子的表达.中华传染病杂志,2003, 1(1):42~ 43
58 Bozkaya H, Bozdayi AM, Aslan N, et al. Circulating IL-2 and IL-10 in chronic active hepatitis C with respect to the response to IFN treatment. Infection, 2000, 28(5): 309~313
59 Thursz M. Genetic susceptibility in chronic viral hepatitis. Antiviral Res, 2001, 52(2): 113~116
60 Domenico L, Calogero C, Rosa DS, et al. IL-10 and TNF-α Polymorphisms and the Recovery from HCV Infection. Human Immunology. 2003, 64(7): 674~680
61 Vidigal PG, Germer JJ, Zein NN. Polymorphisms in the interleukine-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 gene in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol, 2002, 36(2): 271~277
62 Susanne K,Branwen J W,Hennig AJ,et al. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics, 2003, 55(6): 362~369
63 Juszczynski P, Kalinka E, Bienvenu J, et al. Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkilymphoma outcome. Blood, 2002, 100(8): 3037~3040
64 Skoog T, Vant Hooft FM, Kallin B, et al. A common functional polymorphism(C>A substitution at position 863) in the promoter region of the tumor necrosis factor – alpha (TNF-alpha) gene associated with reduced circulating level of TNF-alpha. Hum Mol Genet, 1999, 8(8): 1443~1449
65 Hohler T, Kruger A, Gerken G, et al. A tumor necrosis factor-a(TNF-α) promoter polymorphism is associated with chronic hepatitis B infection. Clin Exp Immunol, 1998, 111(3): 579~582
66 Kim YJ, Lee HS, Im JP, et al. Association of transforming growth factor beta –1 gene polymorphisms with a hepatocellular carcinoma risk inpatients with chronic hepatitis B virus infection. Exp Mol Med, 2003, 35(3): 196~202
67 Lu LP, Li XW, Liu Y, et al. Association of 238G/A polymorphism of tumor necrosis factor alpha gene promoter region with outcomes of hepatitis B virus infection in Chinese Han population. World J Gastroenterol, 2004, 10(12): 1810~1814
68 顾绍庆,朱启镕,俞蕙,等.肿瘤坏死因子-α基因多态性与乙型肝炎病毒宫内感染易感性的关系.中华肝脏病杂志, 2004, 12(9): 538~539
69 Hohler T, Gerken G, Notghi A, et al. HLA-DRB1*1301 and *1302 protect against chronic hepatitis B. J Hepatol, 1997, 26(3): 503~507
70 Rosen HR, McHutchison JG, Conrad AJ, et al. Tumor necrosis factor genetic polymorphisms and response to antiviral therapy to patients with chronic hepatitis C. Am J Gastroenterol, 2002, 97(3): 714~720
71 Mckiernan S, Daly J, Curry MP, et al. Polymorphisms of the TNF-a gene promoter region in hepatitis C infection. Hepatology, 1999, 30(2): 360~365
72 Yee LJ, Tang J, Herrera J, et al. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun, 2000, 1(6): 386~390
73 Kim YJ, Lee HS, Yoon JH, et al. Association of TNF-α promoter polymorphisms with the clearance of hepatitis B virus infection. Hum Mol Genet, 2003, 12(19): 2541~2546
74 Gewaltig J, Mangasser-Stephan K, Gartung C, et al. Association of polymorphisms of the transforming growth factor-beta 1 gene with the rate of progression of HCV-induced liver fibrosis. Clin Chim Acta, 2002, 316(1-2): 83~94
75 Elizabeth E, Catherine J, John L, et al. Host genetic factors influenced disease progression in chronic hepatitis C. Hepatology, 2000, 31(4): 828~ 832
2 Roffi L, Redaelli A, Colloredo G, et al. Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype. Eur J Gastroenterol Hepatol, 2001, 13(5): 501~506
3 Degos F. Natural history of hepatitis C virus infection. Nephrol- dial- transplant, 1996, 11(S4): 16~18
4 文汉成,安社刚,张红芳.抗-HCV 与 HCV-RNA 检测结果不一致原因分析.实用医技杂志,2004,11(8):1707~1708
5 王良华,吴国光,陈刚.荧光定量PCR检测血液中的丙型肝炎病毒(HCV).中国输血杂志,2001,14(S):133
6 中华医学会传染病与寄生虫病学分会、肝病学分会联合修订.病毒性肝炎防治方案.中华传染病杂志,2001,19(1):56~62
7 吴昌烈,郑岚,冯恭文,等.全国血站检验的室间质量评价.中国输血杂志,1997,10(1):51
8 赵继义,刘雪梅,郭薇媛,等.RT 套式 PCR 检测血浆 HCV RNA 及与抗 HCV检测的比较.微生物学杂志,2001,21(4):37~38
9 王乐斌,赵久法.抗-HCV 阴性献血员丙肝病毒感染及意义.临床医学,2000,25(6):442
10 Cieslak PR, Hedberg K, Thomas AR, et al. Hepatitis C virus transmission from an antibody-negative organ and tissue donor---United States. Morb Mortal Wkly Rep, 2003, 52(3):273~276
11 Willems M, Metselaar HJ, Tilanus HW, et al. Liver transplantation and hepatitis C. Transpl Int, 2002; 15(1): 61~72
12 潘宁,张建琼,李丽,等.应用荧光定量 PCR 检测血清中 HCV RNA.东南大学学报(医学版),2003,22(1):16~18
13 王平忠,白雪帆,傅恩清,等.不同基因型丙型肝炎病毒RNA定量分析.第四军医大学学报,2002,23(17):1548~1550
14 魏来,王齐欣,徐小元,等.河北省固安县某农村单采浆献血员丙型肝炎病毒感染的追踪研究.北京大学学报(医学版),2002,34(5):574~578
1 Roffi L, Redaelli A, Colloredo G, et al. Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype. Eur J Gastroenterol Hepatol, 2001, 13(5): 501~506
2 Pan CQ, Zhang JX. Natural History and Clinical Consequences of Hepatitis B Virus Infection. Int J Med Sci, 2005, 2(1):36~40
3 Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community acquired hepatitis C in the United States. N Engl J Med. 1992, 327(27):1899~1905
4 Seder RA, Paul WE. Acquisition of lymphokine-producting phenotype by CD4+ T cells. Annu Rev Immunol, 1994, 12(2):635~674
5 Osna N, Silonova G, Vilgert N, et al. Chronic hepatitis C: T-helper1 / T-helper2 imbalance could cause virus persistence in peripheral blood. Scand J Clin Lab Invest, 1997, 57(8):703~710
6 Paul S, Tabassum S, Islam MN. Interferon- gamma (IFN-gamma) response to different hepatitis B virus antigens in hepatitis B virus infection. Bangladesh Med Res Counc Bull, 2004, 30(2):71~77
7 Pravica V, Perrey C, Stevens A, et al. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Hum Immunol, 2000, 61(9):863~866
8 张平安,吴健民,李艳.IFN-γ基因+ 874 位点单核苷酸多态性与乙型肝炎病毒感染关系的研究.医学临床研究,2005,22(9):1189~1192
9 Pawlowska M, Bishop GA, McGuinness PH, et al. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology, 1996, 24(4):759~765
10 Napoli J, Bishop GA, McGuinness PH, et al. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology, 1996, 24(4): 759~765
11 中华医学会传染病与寄生虫病学分会、肝病学分会联合修订.病毒性肝炎防治方案.中华传染病杂志,2001,19(1):56~62
12 Belardelli F. Role of interferon and other cytokines in the regulation of the immune response. APMIS, 1995, 103(3):161~179
13 Muller U, Steinhoff U, Reis L, et al. Functional role of typeI and type II interferons in antiviral defense. Science, 1994, 264(5167):1918~1921
14 Zhang P, Chen Z, Chen F, et al. Expression of IFN-γ and its receptor alpha in the peripheral blood of patients with chronic hepatitis C. ChineseMedical Journal, 2004, 117(1):79~82
15 Bertoletti A, D'Elios MM, Boni C, et al. Different cytokine profile of intrahepatic T cells in chronic hepatitis B and hepatitis C virus infection. Gastroenterology, 1997, 112(1):193~199
16 Zhao CY, Liu JX, Tang HH, et al. Significance of IL-2 and related indexes in patients with hepatitis and hepatocellular carcinoma. World Chinese Journal of digestion, 1998, 6 (6):479~481
17 Eckels DD, Tabatabail N, Bian TH, et al. In vitro human Th-cell responses to a recombinant hepatitis C virus antigen: Failure in IL-2 production despite proliferation. Hum Immunol, 1999, 60(3):187~199
18 Pawlowska M, Halota W, Smukalska E, et al. Serum IL-2 and sIL-2R concentrations in children with chronic hepatitis B. Pol Merkur Lekarski, 2005, 18(103): 33~35
1 Roffi L, Redaelli A, Colloredo G, et al. Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype. Eur J Gastroenterol Hepatol, 2001, 13(5): 501~506
2 DegosF. Natural history of hepatitis C virus infection. Nephrol- dial-transplant, 1996, 11(S4): 16~18
3 Pan CQ, Zhang JX. Natural History and Clinical Consequences of Hepatitis B Virus Infection. Int J Med Sci, 2005, 2(1): 36~40
4 Cecile G, Heiene C, Jerome C, et al. Lethal Hepatitis After Gene Transfer of IL-4 in the Liver Is Independent of Immune Responses and Dependent on Apoptosis of Hepatocytes: A Rodent Model of IL-4-Induced Hepatitis. The Journal of Immunology, 2001, 166(8): 5225~5235
5 章仕坚,朱宁,林智强,等.各型 HBV 感染中白介素-12、白介素-4 的测定及意义.暨南大学学报(医学版),2004, 25(2):224~226
6 Gramenzi A, Andreone P, Loggi E, et al. Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. Journal of Viral Hepatitis, 2005, 12 (5): 525~530
7 Rosenwasser LJ, Klemm DJ, Dresback JK, et al. Promotor polymorphisms in the chromosome 5 gene cluster in asthma and atopy. Clin Exp Allergy, 1995, 25(S2): 74~78
8 Zhang P, Chen Z, Chen F, et al. Expression of IFN-γ and its receptor alpha in the peripheral blood of patients with chronic hepatitis C. Chinese Medical Journal, 2004, 117(1): 79~82
9 Jia HY, Du J, Zhu SH, et al. Clinical observation of serum IL-18, IL-10 and sIL-2R levels in patients with chronic hepatitis C pre- and post antiviral treatment. Chinese Medical Journal, 2003, 116(4): 605~608
10 Cacciarelli TV, Martinez OM, Gish RG, et al. Immunoregulatory cytokines in chronic hepatitis C virus infection: Pre- and posttreatment with interferon alfa. Hepatology, 1996, 24(1): 6~9
11 Domenico L, Calogero C, Rosa DS, et al. IL-10 and TNF-α Polymorphisms and the Recovery from HCV Infection. Human Immunology. 2003, 64(7): 674~680
12 Vidigal PG, Germer JJ, Zein NN. Polymorphisms in the interleukine-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 gene in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol, 2002, 36(2): 271~277
13 Groux H, Bigler M, de Vries JE, et al. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J Immunol, 1998, 160(7): 3188~3193
14 Vercelli D, Dc Montc L, Monticelli S, et al. To E or not to E? Can an IL-4-induced B cell choose between IgE and IgG4? Int Arch Allergy Immunol, 1998, 116(1): 1~4
15 Turner DM, Williams DM, Sankaran D, et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet, 1997, 46(2): 120~128
16 Peng XM, Huang YS, Ma HH, et al. Interleukin-10 promoter polymorphisms are associated with the mode and sequel of HBeAg seroconversion in patients with chronic hepatitis B virus infection. Liver International, 2006, 26(3): 326~333
17 Shin HD, Park BL, Kim LH, et al. Common interleukin 10 polymorphism associated with decreased risk of tuberculosis. Experimental and Molecular Medicine, 2005, 3(2): 128~132
18 Powell EE, Edwards-Smith CJ, Hay JL, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology, 2000, 31(4): 828~833
19 Barrett S, Collins M, Kenny C, et al. Polymorphisms in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection. J Med Virol, 2003, 71(2): 212~218
20 Cribier B, Schmitt C, Rev D, et al. Porduction of cytokines in patients by hepatitis C virus. J Med Virol, 1998; 55(2): 89~91
21 Kato A, Yoshidome H, Edwards MJ, et al. Reduced hepatic ischemia / reperfusion injury by IL-4: potential anti-inflammatory role of STAT6. Inflammation Res, 2000, 49(6): 275~279
22 Yoshidome H, Kato A, Miyazaki M, et al. IL-13 activates STAT6 and inhibits liver injury induced by ischemia/reperfusion. Am J Pathol, 1999, 155(4): 1059~1064
1 赵根明. 交互作用. 见:李立明, 主编. 临床流行病学.北京: 人民卫生出版社,2002, 143~159
2 Roffi L, Redaelli A, Colloredo G, et al. Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype. Eur J Gastroenterol Hepatol, 2001, 13(5): 501~506
3 Pan CQ, Zhang JX. Natural History and Clinical Consequences of Hepatitis B Virus Infection. Int J Med Sci, 2005, 2(1): 36~40
4 Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community acquired hepatitis C in the United States. N Engl J Med. 1992, 327(27): 1899~1905
5 Romagnani S. The Th1/Th2 paradigm. Immunol Today, 1997, 18(6): 263~266
6 Gramenzi1 A, Andreone1 P, Loggi1 E, et al. Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. J Viral Hepatitis, 2005, 12(5): 525~534
7 Bozkaya H, Bozdayi M, Turkyilmaz R, et al. Circulating IL-2, IL-10 and TNF-alpha in chronic hepatitis B: their relations to HBeAg status and the activity of liver disease. Hepatogastroenterology, 2000, 47(36): 1675~1679
8 Moore JH. The ubiquitous nature of epistasis in determing susceptibility to common human diseases. Hum Hered, 2003, 56(1): 73~82
9 Moore JH, Ritchie MD. The challenges of whole-genome approaches to common diseases. JAMA, 2004, 291(13): 1642~1643
10 Ritchie MD, Hahn LW, Roodi N, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet, 2001, 69(1): 138~147
11 Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interaction. Bioinformatics, 2003, 19(3): 376~382
12 唐迅, 李娜, 胡永华. 应用多因子降维化分析基因-基因交互作用. 中华流行病学杂志.2006,27(5): 437~441
13 Rothman KJ. Epidemiology: an introduction. Oxford, United Kingdom: Oxford University Press, 2002
14 Barrett S, Collins M, Kenny C, et al. Polymorphisms in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection. J Med Virol, 2003, 71(2): 212~218
15 Paul S, Tabassum S, Islam MN. Interferon- gamma (IFN-gamma) response to different hepatitis B virus antigens in hepatitis B virus infection. Bangladesh Med Res Counc Bull, 2004, 30(2): 71~77
16 陈显兵.Th1/Th2 漂移与 HCV 感染慢性化.国际免疫学杂志,2006;29(1): 51~54
1 Kim WR. The burden of hepatitis C in the United States. Hepatology, 2002, 36(5S): 30~34
2 Degos F. Natural history of hepatitis C virus infection. Nephrol Dial Transplant, 1996, 11(S4): 16~18
3 Tran TT, Martin P. Hepatitis B: epidemiology and natural history. Clin Liver Dis, 2004, 8(2): 255~266
4 Kotwal GJ, Baroudy BM, Kuramoto IK, et al. Detection of acute hepatitis C virus infection by ELISA using a synthetic peptide comprising a structural epitope. Proc Natl Acad Sci USA, 1992, 89(10): 4486~4489
5 杨东亮.丙型肝炎的病毒学检测指标及其临床意义.中华肝脏病杂志,2004,12(2):104
6 吴昌烈,郑岚,冯恭文,等.全国血站检验的室间质量评价.中国输血杂志,1997,10(1):51
7 文汉成,安社刚,张红芳.抗-HCV 与 HCV-RNA 检测结果不一致原因分析.实用医技杂志, 2004, 11(8):1707~1708
8 王良华,吴国光,陈刚.荧光定量PCR检测血液中的丙型肝炎病毒(HCV).中国输血杂志,2001,14(S):133
9 王乐斌,赵久法.抗-HCV 阴性献血员丙肝病毒感染及意义.临床医学,2000,25(6):442
10 Centers for Disease Control and Prevention (CDC). Hepatitis C virus transmission from an antibody-negative organ and tissue donor in United States. Morb Mortal Wkly Rep, 2003, 52(13): 273~274
11 Willems M, Metselaar HJ, Tilanus HW, et al. Liver transplantation and hepatitis C. Transpl Int, 2002; 15(2-3): 61~72
12 Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology, 2002, 36(S): 65~73
13 庄辉.重视丙型肝炎的研究.中华肝脏病杂志,2004, 12(2): 65~66
14 邢文革,郑怀竞.必须提高丙型肝炎病毒实验室检验结果的可信度. 中华肝脏病杂志,2004,12(3):170~171
15 Ballardini G, Groff P, Giostra F, et al. Hepatocellular codistribution of c100, c33, c22, and NS5 hepatitisC virus antigens detected by using immunopurified polyclonal spontaneous human antibodies. Hepatology, 1995, 21(5): 730~734
16 Pasquier C, Bujan L, Daudin M, et al. Intermittent detection of hepatitis C virus (HCV) in semen from men with human immunodeficiency virus type 1(HIV-1) and HCV. J Med Virol, 2003, 69(3): 344~349
17 陈佩兰,李琳,田惠英,等.丙型肝炎患者外周血单个核细胞 HCV 和 Fas抗原检测.军医进修学院学报,2000,21(3):215~217
18 Kashiwakuma T, Hasegawa A, Kajita T, et al. Detection of hepatitis C virus specific core protein in serum of patients by a sensitive fluorescence enzyme immunoassay. J Immunol Methods, 1996, 190(1): 79~89
19 Cano H, Candela MJ, Lozano ML, et al. Application of a new enzyme linked immuno sorbent assay for detection of total hepatitis C virus core antigen in blood donors. Transfus Med, 2003, 13(5): 259~266
20 Peterson J, Green G, Lida K, et al. Detection of hepatitis C core antigen in the antibody negative “window” phase of hepatitis C infection. VoxSang, 2000, 78(2): 80~85
21 Lee SR, Peterson J, Niven P, et al. Efficacy of a hepatiits C virus core antigen enzyme linked immuno sorbent assay for the identification of “window phase” blood donations. VoxSang, 2001, 80(1): 19~23
22 Courouce AM, Marrec NL, Bouchardeau F, et al. Efficacy of HCV core antigen detection during the preseroconversion period. Transfusion, 2000, 40(10): 1198~1202
23 Aoyagi K, Ohue C, Lida K, et al. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J Clin Microbiol, 1999, 37(6): 1802~1808
24 Lunel F, Veillon P, Payan C. Evaluation of the Ortho total HCV core antigen assay in comparison to methods of detection and quantification for HCV RNA. Hepatology, 2002; 36(2): 353~357
25 Maynard M, Buti M, Esteban JI, et al. High clinical relevance of total HCVcore antigen testing for monitoring and predicting response to PEG-IFN / ribavirin combination therapy. Hepatology, 2002; 36(2): 359~363
26 Darius M, Takaji W, Tokushige K, et al. Characterization of three novel monoclonal antibodies against hepatitis C virus core protein. J Med Virol, 1996, 48(3): 234~241
27 郭满盈,李谋深,李保仝,等. 献血者血清中 HCV NS3 和核心蛋白抗原的检测及临床意义.中国输血杂志,2001,14(2):78~79
28 中华医学会肝病学分会、中华医学会传染病与寄生虫病学分会.丙型肝炎防治指南.中华流行病学杂志,2004,25(5):369~375
29 吴文娟.HBVe 抗原抗体检测准确性分析.贵州医药,2002,26(5):470
30 赵勇,周影.用PCR技术检测50名HBsAg阴性献血者血清HBV-DNA结果.中国输血杂志,1996,6(4):214
31 安萍,李世拥,韩玲霞,等.PCR 直接法检测 HBsAg 阴性肝病的价值.新消化病学杂志,1996,4(7):385
32 骆抗先,何超,周荣,等.聚合酶链反应对单一抗 HBc 阳性的乙型肝炎病毒携带者的检测.中华医学杂志,1992,72(1):11
33 胡庆宏,刘明跬,陈奕东,等.荧光定量 PCR 在乙型肝炎病毒检测中的应用及临床意义.江西医学院学报,2003,43(4):38~40
34 Brunetto MR, Randone A, Ranki M, et al. Quqntitative analysis of wild type and HbeAg minus hepatitis B viruses by a sequence dependent primer extension assay. J Med Virol, 1994, 43(3): 310~315
35 Hwang SJ, Lu RH, Wood ML, et al. Comparison of the nucleic acid based cross linking hybridization assay and the branched DNA signal amlification assay in the quantitative measurement of serum hepatitis B virus DNA. J Clin Lab Anal, 1999,13(6): 296~300
36 Nolte FS. Branched DNA signal amplification ofr direct quantitation of nucleic acid sequences in clinical specimens. Adv Clin Chem, 1998, 33(2): 201~235
37 Krajden M, Minor JM, Rifkin O, et al. Effect of multiple freeze thaw cycleson hepatitis B virus DNA and hepatitis C virus RNA quantification as measured with branched DNA technology. J Clin Microbiol, 1999, 37(6):1683~1686
38 Hendricks DA, Stowe BJ, Hoo BS, et al. Quantitation of HBV DNA in human serum using a branched DNA (b DNA) signal amplification assay. Am J Clin Pathol, 1995, 104(5): 537~546
39 Jardi R, Buti M, Cotrina M, et al. Quantitative determination of HBV DNA in chronic hepatiits B: comparison of three methods. Gastroenterol Hepatol, 1998, 21(7): 327~331
40 黄建宏,欧兴义,梁小兵,等.乙型肝炎病毒 DNA 检测及其与血清标志物的关系探讨.实用诊断与治疗杂志,2005,19(1):4~5
41 范火亮.乙型肝炎病毒感染者 HBVDNA 与血清病毒标志物的关系.中国基层医药, 2006, 13(1): 64~65
42 Chen RW, Piiparinen H, Seppanen M, et al. Real-time PCR for detection and quantitation of HBV DNA. J Med Virol, 2001,65(2): 250~256
43 Pawlowsky JM, Bastie A, Hezode C, et al. Routine detection and quantification of HBV DNA in clinical laboratories: performance of three commercial assays. J Virol Methods, 2000, 85(1): 11~21
44 陈晓东,陶志华,周武.核酸提取方法在聚合酶链反应测定乙肝病毒核酸中的评价.中华检验医学杂志,2002,25(4):212~214
45 Kimura T, Pokuhara A, Matsumoto A, et al. New Enzyme Immunoassay for Detection of Hepatitis B Virus Core Antigen (HBcAg) and Relation between Levels of HbcAg and HBV DNA. J Clin Microbiology, 2003,41(5): 1901~1906
46 王厚照,田丰丰,陆金霞,等. ELISA 检测乙肝病毒核心抗原的方法建立及应用.中华乙肝防治指南网, 2007.3.5
47 Delfini C, Colloca S, Taliani G, et al. Clearance of hepatitis B virus DNA and pre-S surface antigens in patients with markers of acute viral replication. J Med Virol, 1989,28(2): 169~175
48 张雪红,易长庚,喻淑萍.乙肝患者血清前 S1 蛋白与 HBV-M、HBV-DNA检测结果的分析.中国医师杂志, 2005, 7(1):137~137
49 Yuki N,Hayashi N,Katayama K,et al. Quantitative analysis of Pre-S1 and Pre-S2 in relation to HBsAg expression. Hepatology, 1990, 11(1):38~40
1 Roffi L, Redaelli A, Colloredo G, et al. Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype. Eur J Gastroenterol Hepatol, 2001, 13(5): 501~506
2 Pan CQ, Zhang JX. Natural History and Clinical Consequences of Hepatitis B Virus Infection. Int J Med Sci, 2005, 2(1): 36~40
3 Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community acquired hepatitis C in the United States. N Engl J Med, 1992, 327(27): 1899~1905
4 Tong MJ, Farra NS, Reikes AR, Cl RL. Clinical outcomes after transfusion-associated hepatitis C (see comments). N Engl J Med, 1995, 332(22): 1463~1466
5 Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol, 1999, 31 [S1]: 9~16
6 Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology, 1997, 26(S3): 15~20
7 Poyanard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet, 1997, 349 (9055): 825~832
8 Kenny Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med, 1999, 340(16): 1228~1233
9 Nishimura T, Ohta A. A critical role for antigen-specific Th1 cells in acute liver injury in mice. J Immunol, 1999, 162(11): 6503~6509
10 Rossl S, Marinos G, Caruccl P, et al. Interleutin-12 inducation of Th1 cytokines is impotant for virus clearance in chronic hepatitis B. J Clin Invest, 1997, 99(12): 3025~3033.
11 Weigent DA, Stanton GJ, Johnson HM. Interleukin 2 enhances natural Killer cell activity through induction of gamma interferon. Infect Immun, 1983, 41(3): 992~997
12 Hoffmann SC, Stanley EM, Darrin Cox E, et al. Association of cytokine polymorphic inheritance and in vitro cytokine production in anti- CD3/CD8 -stimulated peripheral blood lymphocytes. Tranplantation, 2001, 72(8): 1444~1452
13 Missale G, Ferrari C, Fiaccadori F. Cytokines mediators in acute inflammation and chronic course of viral hepatitis. Ann Ital Med Int, 1995, 10(1): 14~18
14 Castillo FM, Romero TA, Estevez J, et al. Concentrations of Cytokines, Soluble Interleukin-2 Receptor, and Soluble CD30 in Sera of Patients with Hepatitis B Virus Infection during Acute and Convalescent Phases.Clinical and Diagnostic Laboratory Immunology, 2002, 9(6): 1372~1375
15 Bozkaya H, Bozdayi M, Turkyilmaz R, et al. Circulating IL-2, IL-10 and TNF-alpha in chronic hepatitis B: their relations to HBeAg status and the activity of liver disease. Hepatogastroenterology, 2000,47(36):1675~1679
16 Napoli J, Bishop GA, McGuinness PH, et al. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology,1996, 24(4):759~765
17 Chevillard C, Henri S, Stefani F, et al. Two new polymorphisms in the human interferon gamma (IFN-gamma) promoter. Eur J Immunogenet, 2002, 29(1): 53~56
18 Pravica V, Perrey C, Stevens A, et al. A single nucleotide polymorphism in the first intron of the human IFN-γ gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-γ gene. Hum Immunol, 2000, 61(9):863~866
19 Henri S, Stefani F, Parzy D, et al. Description of three new polymorphisms in the intronic and 3’UTR regions of the human interferon gamma gene. Genes Immun, 2002, 3(1):1~4
20 Lio D, Scola L, Crivello A, et al. Allele frequencies of -874T/A single nucleotide polymorphism at the first intron of interferon-gamma gene in a group of Italian centenarians. Exp Gerontol, 2002, 37(2-3): 315~319
21 Bidwell J, Keen L, Gallagher G, et al. Cytokine polymorphism in human disease. Genes Immun, 2001, 2(1): 61~70
22 张平安,吴健民,李艳.干扰素-γ 基因内含子 1+874 位点多态性与乙型肝炎病毒感染关系的研究.中华流行病学杂志, 2006, 27(1): 41~43
23 Ben Ari Z, Mor E, Papo O, et al. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol. 2003, 98(1): 144~150
24 俞蕙,朱启镕,顾绍庆,等. IFN-γ+874 基因单核苷酸多态性与宫内 HBV感染易感性关系的研究.中华儿科杂志, 2004,42(6):421~423
25 贾因棠,魏来,蒋栋,等.干扰素-γ对丙型肝炎病毒复制子的抑制作用.中华肝脏病杂志, 2006,14(1):7~10
26 Thimme R, Bukh J, Spangenberg HC, et al. Viral and immunological determinants of hepatitis C virus clearance,persistence and disease. Proc Natl Acad Sci USA, 2002, 99(24): 15661~15668
27 Zhang P, Chen Z, Chen F, et al. Expression of IFN-γ and its receptor alpha in the peripheral blood of patients with chronic hepatitis C. Chinese Medical Journal, 2004, 117(1): 79~82
28 路文明,曹文贵.慢性丙型肝炎患者血清 IL-6、IFN-γ的检测意义.肝脏,2002:7(4): 287~288
29 Ben-Ari Z, Pappo O, Druzd T, et al. Role of cytokine gene polymorphism and hepatic transforming growth factor beta1 expression in recurrent hepatitis C after liver transplantation. Cytokine, 2004, 27(1): 7~14
30 Dai CY, Chuang WL, Hsieh MY, et al. Polymorphism of interferon–gamma gene at position-874 and clinical characteristics of chronic hepatitis C. Translational Research, 2006, 148(3): 128~133
31 Cecile G, Heiene C, Jerome C, et al. Lethal Hepatitis After Gene Transfer of IL-4 in the Liver Is Independent of Immune Responses and Dependent on Apoptosis of Hepatocytes: A Rodent Model of IL-4-Induced Hepatitis. The Journal of Immunology, 2001, 166(8): 5225~5235
32 Lohr H F,SchlaakJ FG,Gerken B, et al. Phenotypical analysis and cytokine release of liver-infiltrating and peripheral blood T lymphocytes from patients with chronic hepatitis of different etiology. Liver, 1994, 14(2): 161~166
33 Martinez OM, Villanueva JC, Greshwin E, et al. Cytokine patterns and cytotoxic mediators in primary biliary cirrhosis. Hepathology, 1995, 21(1): 113~119
34 Rosenwasser LJ, Klemm DJ, Dresback JK, et al. Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy. Clin Exp Allergy,1995, 25(S):74~78
35 章仕坚,朱宁,林智强,等.各型 HBV 感染中白介素-12、白介素-4 的测定及意义.暨南大学学报(医学版), 2004, 25(2): 224~226
36 王坤,时昌文,高勇,等.中国北方两市部分人群 IL-2、IL-4 基因多态性 与 乙 肝 关 联 性 的 研 究 . 中 国 现 代 普 通 外 科 进展,2006,11(3):117~123
37 朱启镕,顾绍庆,俞惠,等.细胞因子基因多态性与乙型肝炎病毒宫内感染易感性的研究.中华流行病学杂志,2005,26(4):236~239
38 Gramenzi A, Andreoe P, Loggi E, et al. Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. Journal of Viral Hepatitis,2005,12(5): 525~534
39 Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin –6 transcriptional regulation. J Biol Chem, 2000, 275(24):18138~18144
40 Park BL, Lee HS, Kim YJ, et al. Association between interleukin 6 promoter variants and chronic hepatitis B progression. Exp Mol Med, 2003, 35(2): 76~82
41 Barrett S, Collins M, Kenny C, et al. Polymorphisms in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection. J Med Virol, 2003, 71(2): 212~218
42 Gibbs VC, Pennica D. CRF2-4: isolation of cDNA clones encoding the human and mouse proteins. Gene, 1997, 186(1): 97~101
43 Im SH, Hueber A, Monticelli S, et al. Chromatin-level regulation of the IL10 gene in T cells. J Biol Chem, 2004, 279(45): 46818~46825
44 Moore KW, de Waal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol, 2001, 19(4): 683~765
45 Ito S, Ansari P, Sakatsume M, et al. Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma- induced genes by suppressing tyrosine phosphorylation of STAT1. Blood, 1999, 93(5): 1456-1463
46 Nelson DR, Lauwers GY, Lau JY, et al. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology, 2000, 118(4): 655~660
47 Louis H, Le Moine O, Peny MO, et al. Production and role ofinterleukin-10 in concanavalin A-induced hepatitis in mice. Hepatology, 1997, 25(6): 1382~1389
48 Louis H, Van Laethem JL, Wu W, et al. Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice. Hepatology, 1998, 28(6): 1607~1615
49 Edwards-Smith CJ, Jonsson JR, Purdie DM, et al. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology, 1999; 30(2): 526~530
50 Thompson K, Maltby J, Fallowfield J, et al. Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis. Hepatology, 1998, 28(6): 1597~1606
51 Turner DM, Williams DM, Sankaran D, et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet, 1997, 24(1): 1~8
52 Miura Y, Thoburn CJ, Bright EC, et al. Cytokine and chemokine profiles in autologous graft-versus-host disease (GVHD): interleukin 10 and interferon gamma may be critical mediators for the development of autologous GVHD. Blood, 2002, 100(7): 2650~2658
53 Eskdale J, Gallagher G, Verweij CL, et al. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA, 1998, 95(16): 9465~9470
54 Mangia A, Santoro R, Piattelli M, et al. IL-10 haplotypes as possible predictors of spontaneous clearance of HCV infection. Cytokine, 2004, 25(3): 103~109
55 Miyazoe S, Hamasaki K, Nakata K, et al. Influence of interleukine-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus. Am J Gastroenterol, 2002, 97(8): 2086~ 2092
56 吴晓蔓, 郭海波.慢性乙型肝炎患者血清 IL-10 与 HBVDNA 复制水平检测及临床意义. 临床肝胆病杂志, 2004, 20(3): 151~152
57 张萍,颜学兵,吴文漪,等.慢性乙型肝炎患者外周血单个核细胞 Th1、T型细胞标志物及其细胞因子的表达.中华传染病杂志,2003, 1(1):42~ 43
58 Bozkaya H, Bozdayi AM, Aslan N, et al. Circulating IL-2 and IL-10 in chronic active hepatitis C with respect to the response to IFN treatment. Infection, 2000, 28(5): 309~313
59 Thursz M. Genetic susceptibility in chronic viral hepatitis. Antiviral Res, 2001, 52(2): 113~116
60 Domenico L, Calogero C, Rosa DS, et al. IL-10 and TNF-α Polymorphisms and the Recovery from HCV Infection. Human Immunology. 2003, 64(7): 674~680
61 Vidigal PG, Germer JJ, Zein NN. Polymorphisms in the interleukine-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 gene in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol, 2002, 36(2): 271~277
62 Susanne K,Branwen J W,Hennig AJ,et al. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics, 2003, 55(6): 362~369
63 Juszczynski P, Kalinka E, Bienvenu J, et al. Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkilymphoma outcome. Blood, 2002, 100(8): 3037~3040
64 Skoog T, Vant Hooft FM, Kallin B, et al. A common functional polymorphism(C>A substitution at position 863) in the promoter region of the tumor necrosis factor – alpha (TNF-alpha) gene associated with reduced circulating level of TNF-alpha. Hum Mol Genet, 1999, 8(8): 1443~1449
65 Hohler T, Kruger A, Gerken G, et al. A tumor necrosis factor-a(TNF-α) promoter polymorphism is associated with chronic hepatitis B infection. Clin Exp Immunol, 1998, 111(3): 579~582
66 Kim YJ, Lee HS, Im JP, et al. Association of transforming growth factor beta –1 gene polymorphisms with a hepatocellular carcinoma risk inpatients with chronic hepatitis B virus infection. Exp Mol Med, 2003, 35(3): 196~202
67 Lu LP, Li XW, Liu Y, et al. Association of 238G/A polymorphism of tumor necrosis factor alpha gene promoter region with outcomes of hepatitis B virus infection in Chinese Han population. World J Gastroenterol, 2004, 10(12): 1810~1814
68 顾绍庆,朱启镕,俞蕙,等.肿瘤坏死因子-α基因多态性与乙型肝炎病毒宫内感染易感性的关系.中华肝脏病杂志, 2004, 12(9): 538~539
69 Hohler T, Gerken G, Notghi A, et al. HLA-DRB1*1301 and *1302 protect against chronic hepatitis B. J Hepatol, 1997, 26(3): 503~507
70 Rosen HR, McHutchison JG, Conrad AJ, et al. Tumor necrosis factor genetic polymorphisms and response to antiviral therapy to patients with chronic hepatitis C. Am J Gastroenterol, 2002, 97(3): 714~720
71 Mckiernan S, Daly J, Curry MP, et al. Polymorphisms of the TNF-a gene promoter region in hepatitis C infection. Hepatology, 1999, 30(2): 360~365
72 Yee LJ, Tang J, Herrera J, et al. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun, 2000, 1(6): 386~390
73 Kim YJ, Lee HS, Yoon JH, et al. Association of TNF-α promoter polymorphisms with the clearance of hepatitis B virus infection. Hum Mol Genet, 2003, 12(19): 2541~2546
74 Gewaltig J, Mangasser-Stephan K, Gartung C, et al. Association of polymorphisms of the transforming growth factor-beta 1 gene with the rate of progression of HCV-induced liver fibrosis. Clin Chim Acta, 2002, 316(1-2): 83~94
75 Elizabeth E, Catherine J, John L, et al. Host genetic factors influenced disease progression in chronic hepatitis C. Hepatology, 2000, 31(4): 828~ 832